|
G |
S100b |
S100 calcium binding protein B |
increases expression |
ISO |
beta-1,3-D-glucan results in increased expression of S100B protein |
CTD |
PMID:28117141 |
|
NCBI chr20:13,130,633...13,142,856
Ensembl chr20:13,130,636...13,142,856
|
|
G |
Tslp |
thymic stromal lymphopoietin |
increases expression |
ISO |
(1->3)-beta-D-glucan increases expression of TSLP mRNA and protein in corneal epithelial cells |
RGD |
PMID:26874828 |
RGD:38549373 |
NCBI chr18:25,613,601...25,618,066
Ensembl chr18:25,613,831...25,617,361
|
|
G |
Uchl1 |
ubiquitin C-terminal hydrolase L1 |
increases expression |
ISO |
beta-1,3-D-glucan results in increased expression of UCHL1 protein |
CTD |
PMID:28117141 |
|
NCBI chr14:43,133,224...43,143,942
Ensembl chr14:43,133,218...43,143,973
|
|
|
G |
Nos2 |
nitric oxide synthase 2 |
increases expression |
EXP |
Cellulose analog results in increased expression of NOS2 protein |
CTD |
PMID:29458016 |
|
NCBI chr10:66,188,290...66,221,621
Ensembl chr10:66,189,786...66,313,190
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
increases expression |
EXP |
Cellulose analog results in increased expression of PTGS2 protein |
CTD |
PMID:29458016 |
|
NCBI chr13:67,351,230...67,356,920
Ensembl chr13:67,351,087...67,359,335
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
Cellulose analog inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of TNF mRNA] |
CTD |
PMID:21354485 |
|
NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
|
|
|
G |
Fgf7 |
fibroblast growth factor 7 |
increases expression |
ISO |
arabinoxylan results in increased expression of FGF7 mRNA |
CTD |
PMID:15678371 |
|
NCBI chr 3:118,315,859...118,368,464
Ensembl chr 3:118,317,761...118,366,872
|
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions |
ISO |
betadex inhibits the reaction [sodium arsenite results in increased phosphorylation of AKT1 protein] |
CTD |
PMID:12614848 |
|
NCBI chr 6:137,218,398...137,239,970
Ensembl chr 6:137,218,376...137,236,258
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
ISO |
betadex inhibits the reaction [sodium arsenite results in increased phosphorylation of JUN protein] |
CTD |
PMID:11035063 |
|
NCBI chr 5:114,011,184...114,014,277
Ensembl chr 5:114,011,189...114,014,277
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
ISO |
betadex inhibits the reaction [sodium arsenite results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:11035063 |
|
NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
ISO |
betadex inhibits the reaction [sodium arsenite results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:11035063 |
|
NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions |
ISO |
betadex inhibits the reaction [sodium arsenite results in increased cleavage of PARP1 protein] |
CTD |
PMID:11035063 |
|
NCBI chr13:98,857,255...98,889,444
Ensembl chr13:98,857,177...98,889,716
|
|
G |
Tfeb |
transcription factor EB |
affects localization |
ISO |
betadex affects the localization of TFEB protein |
CTD |
PMID:28366621 |
|
NCBI chr 9:15,208,141...15,264,101
Ensembl chr 9:15,207,822...15,214,596
|
|
G |
Thy1 |
Thy-1 cell surface antigen |
multiple interactions |
ISO |
betadex inhibits the reaction [sodium arsenite promotes the reaction [THY1 protein binds to THY1 protein]] |
CTD |
PMID:11035063 |
|
NCBI chr 8:48,382,121...48,387,271
Ensembl chr 8:48,382,121...48,386,935
|
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
increases expression |
ISO |
beta-Glucans results in increased expression of CCL2 protein |
CTD |
PMID:17572156 |
|
NCBI chr10:69,412,065...69,413,863
Ensembl chr10:69,412,017...69,413,870
|
|
G |
Cd40 |
CD40 molecule |
increases expression |
ISO |
beta-Glucans results in increased expression of CD40 protein |
CTD |
PMID:17572156 |
|
NCBI chr 3:161,519,789...161,534,943
Ensembl chr 3:161,519,743...161,534,704
|
|
G |
Cd69 |
Cd69 molecule |
increases expression |
ISO |
beta-Glucans results in increased expression of CD69 protein |
CTD |
PMID:17572156 |
|
NCBI chr 4:163,041,147...163,049,065
Ensembl chr 4:163,041,141...163,049,084
|
|
G |
Cd80 |
Cd80 molecule |
increases expression |
ISO |
beta-Glucans results in increased expression of CD80 protein |
CTD |
PMID:17572156 |
|
NCBI chr11:64,815,201...64,855,293
Ensembl chr11:64,827,635...64,855,353
|
|
G |
Cd86 |
CD86 molecule |
increases expression |
ISO |
beta-Glucans results in increased expression of CD86 protein |
CTD |
PMID:17572156 |
|
NCBI chr11:67,060,305...67,117,990
Ensembl chr11:67,082,193...67,118,795
|
|
G |
Fmo2 |
flavin containing dimethylaniline monoxygenase 2 |
increases expression |
ISO |
beta-Glucans results in increased expression of FMO2 mRNA |
CTD |
PMID:27910771 |
|
NCBI chr13:80,752,526...80,775,264
Ensembl chr13:80,755,058...80,775,264
|
|
G |
Fmo3 |
flavin containing dimethylaniline monoxygenase 3 |
increases expression |
ISO |
beta-Glucans results in increased expression of FMO3 mRNA |
CTD |
PMID:27910771 |
|
NCBI chr13:80,837,418...80,856,214
Ensembl chr13:80,837,420...80,862,963
|
|
G |
Fmo4 |
flavin containing dimethylaniline monoxygenase 4 |
increases expression |
ISO |
beta-Glucans results in increased expression of FMO4 mRNA |
CTD |
PMID:27910771 |
|
NCBI chr13:80,685,385...80,703,575
Ensembl chr13:80,685,325...80,703,615
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
ISO |
[beta-Glucans co-treated with resiquimod co-treated with IFNG protein] results in increased expression of IL12A mRNA; IFNG protein inhibits the reaction [beta-Glucans results in increased expression of [IL12B protein binds to IL23A protein]]; IFNG protein inhibits the reaction [beta-Glucans results in increased expression of IL10 mRNA]; IFNG protein inhibits the reaction [beta-Glucans results in increased expression of IL10 protein]; IFNG protein inhibits the reaction [beta-Glucans results in increased expression of IL23A mRNA]; IFNG protein promotes the reaction [beta-Glucans results in increased expression of [IL12A protein binds to IL12B protein]] |
CTD |
PMID:18490488 |
|
NCBI chr 7:61,337,383...61,341,419
Ensembl chr 7:61,337,381...61,341,419
|
|
G |
Il10 |
interleukin 10 |
increases expression multiple interactions |
ISO |
beta-Glucans results in increased expression of IL10 mRNA; beta-Glucans results in increased expression of IL10 protein IFNG protein inhibits the reaction [beta-Glucans results in increased expression of IL10 mRNA]; IFNG protein inhibits the reaction [beta-Glucans results in increased expression of IL10 protein]; resiquimod promotes the reaction [beta-Glucans results in increased expression of IL10 mRNA]; resiquimod promotes the reaction [beta-Glucans results in increased expression of IL10 protein] |
CTD |
PMID:18490488 |
|
NCBI chr13:47,738,933...47,743,392
Ensembl chr13:47,739,526...47,743,392
|
|
G |
Il12a |
interleukin 12A |
multiple interactions |
ISO |
[beta-Glucans co-treated with resiquimod co-treated with IFNG protein] results in increased expression of IL12A mRNA; [beta-Glucans co-treated with resiquimod] results in increased expression of [IL12A protein binds to IL12B protein]; IFNG protein promotes the reaction [beta-Glucans results in increased expression of [IL12A protein binds to IL12B protein]] |
CTD |
PMID:18490488 |
|
NCBI chr 2:165,076,945...165,083,996
Ensembl chr 2:165,076,607...165,084,318
|
|
G |
Il12b |
interleukin 12B |
multiple interactions increases expression |
ISO |
[beta-Glucans co-treated with resiquimod] results in increased expression of [IL12A protein binds to IL12B protein]; beta-Glucans results in increased expression of [IL12B protein binds to IL23A protein]; IFNG protein inhibits the reaction [beta-Glucans results in increased expression of [IL12B protein binds to IL23A protein]]; IFNG protein promotes the reaction [beta-Glucans results in increased expression of [IL12A protein binds to IL12B protein]]; resiquimod promotes the reaction [beta-Glucans results in increased expression of [IL12B protein binds to IL23A protein]]; resiquimod promotes the reaction [beta-Glucans results in increased expression of IL12B protein] |
CTD |
PMID:18490488 |
|
NCBI chr10:30,034,447...30,048,774
Ensembl chr10:30,038,709...30,048,085
|
|
G |
Il23a |
interleukin 23 subunit alpha |
multiple interactions increases expression |
ISO |
beta-Glucans results in increased expression of [IL12B protein binds to IL23A protein]; IFNG protein inhibits the reaction [beta-Glucans results in increased expression of [IL12B protein binds to IL23A protein]]; IFNG protein inhibits the reaction [beta-Glucans results in increased expression of IL23A mRNA]; resiquimod promotes the reaction [beta-Glucans results in increased expression of [IL12B protein binds to IL23A protein]]; resiquimod promotes the reaction [beta-Glucans results in increased expression of IL23A mRNA] |
CTD |
PMID:18490488 |
|
NCBI chr 7:2,710,609...2,712,723
Ensembl chr 7:2,710,609...2,712,723
|
|
G |
Il6 |
interleukin 6 |
multiple interactions increases expression |
ISO |
3,3',4,5'-tetrahydroxystilbene inhibits the reaction [beta-Glucans results in increased expression of IL6 protein]; MYD88 gene mutant form inhibits the reaction [beta-Glucans results in increased secretion of IL6 protein] |
CTD |
PMID:17572156 |
|
NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
|
|
G |
Myd88 |
MYD88, innate immune signal transduction adaptor |
multiple interactions |
ISO |
MYD88 gene mutant form inhibits the reaction [beta-Glucans results in increased secretion of IL6 protein]; MYD88 gene mutant form inhibits the reaction [beta-Glucans results in increased secretion of TNF protein] |
CTD |
PMID:17572156 |
|
NCBI chr 8:128,022,512...128,027,462
Ensembl chr 8:128,022,473...128,026,841
|
|
G |
Syk |
spleen associated tyrosine kinase |
increases phosphorylation |
ISO |
beta-Glucans results in increased phosphorylation of SYK protein |
CTD |
PMID:17572156 |
|
NCBI chr17:12,614,311...12,669,568
Ensembl chr17:12,614,311...12,669,573
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions increases expression |
ISO |
3,3',4,5'-tetrahydroxystilbene inhibits the reaction [beta-Glucans results in increased expression of TNF protein]; MYD88 gene mutant form inhibits the reaction [beta-Glucans results in increased secretion of TNF protein] |
CTD |
PMID:17572156 |
|
NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
|
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
increases phosphorylation multiple interactions |
ISO |
Carrageenan results in increased phosphorylation of AKT1 protein fucoxanthin inhibits the reaction [Carrageenan results in increased phosphorylation of AKT1 protein] |
CTD |
PMID:26418808 |
|
NCBI chr 6:137,218,398...137,239,970
Ensembl chr 6:137,218,376...137,236,258
|
|
G |
Anxa1 |
annexin A1 |
affects response to substance multiple interactions |
ISO |
ANXA1 protein affects the susceptibility to Carrageenan ANXA1 protein affects the susceptibility to [Dexamethasone co-treated with Carrageenan] |
CTD |
PMID:12475898 |
|
NCBI chr 1:237,893,983...237,910,002
Ensembl chr 1:237,893,966...237,910,012
|
|
G |
Apcs |
amyloid P component, serum |
increases expression |
EXP |
Carrageenan results in increased expression of APCS protein |
CTD |
PMID:22330755 |
|
NCBI chr13:91,426,621...91,427,417
Ensembl chr13:91,426,479...91,427,575
|
|
G |
Cat |
catalase |
multiple interactions decreases activity |
ISO EXP |
fucoxanthin inhibits the reaction [Carrageenan results in decreased activity of CAT protein] procyanidin B2 inhibits the reaction [Carrageenan results in decreased activity of CAT protein] |
CTD |
PMID:26418808 PMID:28844677 |
|
NCBI chr 3:93,379,872...93,412,058
Ensembl chr 3:93,379,874...93,412,058
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions increases expression |
ISO |
5S,12R,18R-trihydroxy-6Z,8E,10E,14Z,16E-eicosapentaenoic acid inhibits the reaction [Carrageenan results in increased expression of CCL2 protein] |
CTD |
PMID:12444156 PMID:20383154 |
|
NCBI chr10:69,412,065...69,413,863
Ensembl chr10:69,412,017...69,413,870
|
|
G |
Ccl3 |
C-C motif chemokine ligand 3 |
multiple interactions increases expression |
ISO |
5S,12R,18R-trihydroxy-6Z,8E,10E,14Z,16E-eicosapentaenoic acid inhibits the reaction [Carrageenan results in increased expression of CCL3 protein] |
CTD |
PMID:12444156 PMID:20383154 |
|
NCBI chr10:70,869,516...70,871,066
Ensembl chr10:70,869,513...70,871,066
|
|
G |
Ccl5 |
C-C motif chemokine ligand 5 |
increases expression multiple interactions |
ISO EXP |
Carrageenan results in increased expression of CCL5 protein isoquercitrin inhibits the reaction [Carrageenan results in increased expression of CCL5 protein]; Quercetin inhibits the reaction [Carrageenan results in increased expression of CCL5 protein] |
CTD |
PMID:12444156 PMID:14654164 |
|
NCBI chr10:70,739,764...70,744,303
Ensembl chr10:70,739,800...70,744,315
|
|
G |
Cma1 |
chymase 1 |
multiple interactions increases expression |
EXP |
adelmidrol inhibits the reaction [Carrageenan results in increased expression of CMA1 protein] |
CTD |
PMID:18429935 |
|
NCBI chr15:34,601,037...34,603,819
Ensembl chr15:34,601,037...34,603,819
|
|
G |
Cxcl2 |
C-X-C motif chemokine ligand 2 |
multiple interactions increases secretion increases expression |
EXP ISO |
IMMLG5521 inhibits the reaction [Carrageenan results in increased secretion of CXCL2 protein]; isoquercitrin inhibits the reaction [Carrageenan results in increased expression of CXCL2 protein] |
CTD |
PMID:12444156 PMID:14654164 PMID:21549112 |
|
NCBI chr14:18,731,346...18,733,391
Ensembl chr14:18,731,378...18,733,391
|
|
G |
Cxcl3 |
C-X-C motif chemokine ligand 3 |
increases expression |
ISO |
Carrageenan results in increased expression of CXCL1 protein |
CTD |
PMID:12444156 |
|
NCBI chr14:18,820,168...18,839,659
Ensembl chr14:18,820,168...18,839,595
|
|
G |
Egr1 |
early growth response 1 |
increases expression multiple interactions |
ISO |
Carrageenan results in increased expression of EGR1 protein 3-(4-methylphenylsulfonyl)-2-propenenitrile inhibits the reaction [Carrageenan results in increased expression of EGR1 protein]; EGR1 protein inhibits the reaction [Carrageenan results in decreased expression of and affects the localization of TJP1 protein]; NFKBIA protein inhibits the reaction [Carrageenan results in increased expression of EGR1 protein] |
CTD |
PMID:22561171 |
|
NCBI chr18:27,657,903...27,660,101
Ensembl chr18:27,657,628...27,661,429
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
multiple interactions increases expression |
EXP |
3-(1,2,5,6-tetrahydropyrid-4-yl)pyrrolo(3,2-b)pyrid-5-one inhibits the reaction [Carrageenan results in increased expression of FOS protein]; Flurbiprofen inhibits the reaction [Carrageenan results in increased expression of FOS protein]; Flurbiprofen promotes the reaction [Urethane inhibits the reaction [Carrageenan results in increased expression of FOS protein]]; Urethane inhibits the reaction [Carrageenan results in increased expression of FOS protein]; Urethane inhibits the reaction [Flurbiprofen inhibits the reaction [Carrageenan results in increased expression of FOS protein]] |
CTD |
PMID:1327382 PMID:11164833 |
|
NCBI chr 6:109,300,433...109,303,299
Ensembl chr 6:109,300,433...109,303,299
|
|
G |
Gal |
galanin and GMAP prepropeptide |
decreases response to substance |
ISO |
GAL protein results in decreased susceptibility to Carrageenan |
CTD |
PMID:17999197 |
|
NCBI chr 1:218,653,059...218,657,922
Ensembl chr 1:218,652,917...218,657,925
|
|
G |
Gpr132 |
G protein-coupled receptor 132 |
increases expression |
ISO |
Carrageenan results in increased expression of GPR132 mRNA |
CTD |
PMID:19602228 |
|
NCBI chr 6:137,652,213...137,671,658
Ensembl chr 6:137,652,213...137,664,133
|
|
G |
Gpr4 |
G protein-coupled receptor 4 |
increases expression |
ISO |
Carrageenan results in increased expression of GPR4 mRNA |
CTD |
PMID:19602228 |
|
NCBI chr 1:80,125,639...80,136,786
Ensembl chr 1:80,135,391...80,136,880
|
|
G |
Gpr65 |
G-protein coupled receptor 65 |
increases expression |
ISO |
Carrageenan results in increased expression of GPR65 mRNA |
CTD |
PMID:19602228 |
|
NCBI chr 6:122,248,528...122,256,115
Ensembl chr 6:122,254,841...122,256,251
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions decreases expression |
EXP |
procyanidin B2 inhibits the reaction [Carrageenan results in decreased expression of HMOX1 protein] |
CTD |
PMID:28844677 |
|
NCBI chr19:14,508,634...14,515,455
Ensembl chr19:14,508,616...14,515,456
|
|
G |
Hspa1a |
heat shock protein family A (Hsp70) member 1A |
increases expression |
EXP |
Carrageenan results in increased expression of HSPA1A protein |
CTD |
PMID:15860553 |
|
NCBI chr20:4,875,834...4,881,751
Ensembl chr20:4,877,324...4,879,779
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
multiple interactions increases expression |
EXP ISO |
2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [rosiglitazone inhibits the reaction [Carrageenan results in increased expression of ICAM1 protein]]; Carrageenan promotes the reaction [Lipopolysaccharides results in increased expression of ICAM1 mRNA]; Dexamethasone inhibits the reaction [Carrageenan results in increased expression of ICAM1 mRNA]; Fluvoxamine inhibits the reaction [Carrageenan results in increased expression of ICAM1 mRNA]; imisopasem manganese inhibits the reaction [Carrageenan results in increased expression of ICAM1 protein]; rosiglitazone inhibits the reaction [Carrageenan results in increased expression of ICAM1 protein] IL1R1 protein promotes the reaction [Carrageenan results in increased expression of ICAM1 protein]; PEGylated soluble tumor necrosis factor receptor I inhibits the reaction [Carrageenan results in increased expression of ICAM1 protein]; TNFSF8 protein promotes the reaction [Carrageenan results in increased expression of ICAM1 protein] Carrageenan results in increased expression of ICAM1 mRNA; Carrageenan results in increased expression of ICAM1 protein |
CTD |
PMID:11181422 PMID:14709329 PMID:15380531 PMID:22330755 PMID:27803785 |
|
NCBI chr 8:22,035,287...22,047,049
Ensembl chr 8:22,035,256...22,047,059
|
|
G |
Il10 |
interleukin 10 |
increases secretion multiple interactions increases expression |
EXP ISO |
Carrageenan results in increased secretion of IL10 protein indole-3-guanylhydrazone hydrochloride promotes the reaction [Carrageenan results in increased secretion of IL10 protein]; Indomethacin promotes the reaction [Carrageenan results in increased secretion of IL10 protein] Indomethacin inhibits the reaction [Carrageenan results in increased expression of IL10 mRNA]; procyanidin B2 inhibits the reaction [Carrageenan results in increased secretion of IL10 protein]; Thioctic Acid promotes the reaction [Carrageenan results in increased expression of IL10 mRNA] |
CTD |
PMID:11181422 PMID:19735303 PMID:28844677 PMID:29499192 |
|
NCBI chr13:47,738,933...47,743,392
Ensembl chr13:47,739,526...47,743,392
|
|
G |
Il1a |
interleukin 1 alpha |
multiple interactions decreases expression |
ISO |
Carrageenan inhibits the reaction [Morphine results in decreased expression of IL1A protein]; Dexamethasone inhibits the reaction [Carrageenan inhibits the reaction [Morphine results in decreased expression of IL1A protein]]; Dexamethasone inhibits the reaction [Morphine inhibits the reaction [Carrageenan results in decreased expression of IL1A protein]]; Morphine inhibits the reaction [Carrageenan results in decreased expression of IL1A protein]; Naloxone inhibits the reaction [Carrageenan inhibits the reaction [Morphine results in decreased expression of IL1A protein]]; Naloxone inhibits the reaction [Morphine inhibits the reaction [Carrageenan results in decreased expression of IL1A protein]] |
CTD |
PMID:12182845 |
|
NCBI chr 3:121,824,712...121,836,122
Ensembl chr 3:121,825,412...121,836,086
|
|
G |
Il1b |
interleukin 1 beta |
increases secretion increases expression multiple interactions |
ISO EXP |
Carrageenan results in increased secretion of IL1B protein Carrageenan results in increased expression of IL1B protein 5S,12R,18R-trihydroxy-6Z,8E,10E,14Z,16E-eicosapentaenoic acid inhibits the reaction [Carrageenan results in increased expression of IL1B protein]; indole-3-guanylhydrazone hydrochloride inhibits the reaction [Carrageenan results in increased secretion of IL1B protein]; Indomethacin inhibits the reaction [Carrageenan results in increased secretion of IL1B protein] 3-methylquercetin inhibits the reaction [Carrageenan results in increased expression of IL1B protein]; budlein A inhibits the reaction [Carrageenan results in increased secretion of IL1B protein]; Carrageenan promotes the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]; Dexamethasone inhibits the reaction [Carrageenan results in increased expression of IL1B protein]; imisopasem manganese inhibits the reaction [Carrageenan results in increased expression of IL1B protein]; IMMLG5521 inhibits the reaction [Carrageenan results in increased secretion of IL1B protein]; N-(2-hydroxybenzoyl)tyramine inhibits the reaction [Carrageenan results in increased expression of IL1B protein] |
CTD |
PMID:11181422 PMID:16368644 PMID:17320857 PMID:20383154 PMID:21549112 PMID:22330755 PMID:23774260 PMID:23872256 PMID:29499192 |
|
NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
|
|
G |
Il1r1 |
interleukin 1 receptor type 1 |
multiple interactions increases response to substance |
ISO |
IL1R1 protein promotes the reaction [Carrageenan results in increased expression of ICAM1 protein]; IL1R1 protein promotes the reaction [Carrageenan results in increased expression of SELP protein]; IL1R1 protein promotes the reaction [Carrageenan results in increased expression of TNF protein]; IL1R1 protein promotes the reaction [Carrageenan results in increased expression of TNFRSF8 protein]; IL1R1 protein promotes the reaction [Carrageenan results in increased expression of TNFSF8 protein] IL1R1 protein results in increased susceptibility to Carrageenan |
CTD |
PMID:15380531 |
|
NCBI chr 9:46,962,291...47,038,139
Ensembl chr 9:46,962,288...47,036,670
|
|
G |
Il6 |
interleukin 6 |
multiple interactions increases expression increases secretion |
ISO EXP |
5S,12R,18R-trihydroxy-6Z,8E,10E,14Z,16E-eicosapentaenoic acid inhibits the reaction [Carrageenan results in increased expression of IL6 protein] 3-methylquercetin inhibits the reaction [Carrageenan results in increased expression of IL6 protein]; Carrageenan promotes the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]; Diclofenac inhibits the reaction [Carrageenan results in increased expression of IL6 protein]; imisopasem manganese inhibits the reaction [Carrageenan results in increased expression of IL6 protein]; procyanidin B2 inhibits the reaction [Carrageenan results in increased secretion of IL6 protein]; Thiazolidines analog inhibits the reaction [Carrageenan results in increased expression of IL6 protein] |
CTD |
PMID:11181422 PMID:20383154 PMID:22330755 PMID:23774260 PMID:24412305 PMID:28844677 |
|
NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
|
|
G |
Klk7 |
kallikrein-related peptidase 7 |
increases expression multiple interactions |
EXP |
Carrageenan results in increased expression of KLK3 protein procyanidin B2 inhibits the reaction [Carrageenan results in increased expression of KLK3 protein] |
CTD |
PMID:28844677 |
|
NCBI chr 1:99,749,991...99,754,723
Ensembl chr 1:99,749,936...99,754,435
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
increases phosphorylation multiple interactions |
ISO |
Carrageenan results in increased phosphorylation of MAPK1 protein fucoxanthin inhibits the reaction [Carrageenan results in increased phosphorylation of MAPK1 protein]; Indomethacin inhibits the reaction [Carrageenan results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:26418808 |
|
NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions increases phosphorylation |
ISO |
fucoxanthin inhibits the reaction [Carrageenan results in increased phosphorylation of MAPK3 protein]; Indomethacin inhibits the reaction [Carrageenan results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:26418808 |
|
NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
increases expression multiple interactions |
EXP |
Carrageenan results in increased expression of MMP9 protein adelmidrol inhibits the reaction [Carrageenan results in increased expression of MMP9 protein] |
CTD |
PMID:18429935 |
|
NCBI chr 3:161,413,410...161,421,473
Ensembl chr 3:161,413,298...161,421,520
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions increases activity increases expression |
EXP |
adelmidrol inhibits the reaction [Carrageenan results in increased activity of MPO protein]; arvelexin analog inhibits the reaction [Carrageenan results in increased expression of MPO protein]; Carrageenan inhibits the reaction [Raloxifene Hydrochloride results in increased activity of MPO protein]; Dexamethasone inhibits the reaction [Carrageenan results in increased activity of MPO protein]; Diclofenac inhibits the reaction [Carrageenan results in increased activity of MPO protein]; Ibuprofen inhibits the reaction [Carrageenan results in increased expression of MPO protein]; manganese(III)-tetrakis(4-benzoic acid)porphyrin inhibits the reaction [Carrageenan results in increased activity of MPO protein]; N-(2-hydroxybenzoyl)tyramine inhibits the reaction [Carrageenan results in increased activity of MPO protein]; Thiazolidines analog inhibits the reaction [Carrageenan results in increased activity of MPO protein] |
CTD |
PMID:9890637 PMID:15860553 PMID:18429935 PMID:23872256 PMID:24412305 PMID:25451575 |
|
NCBI chr10:75,087,892...75,098,260
Ensembl chr10:75,087,892...75,098,260
|
|
G |
Mt1 |
metallothionein 1 |
multiple interactions |
ISO |
[Methylnitrosourea co-treated with Carrageenan] results in increased expression of MT1 protein |
CTD |
PMID:15928667 |
|
NCBI chr19:11,301,991...11,303,007
Ensembl chr17:78,793,336...78,793,724
|
|
G |
Nfe2l2 |
nuclear factor, erythroid 2-like 2 |
affects localization multiple interactions |
EXP |
Carrageenan affects the localization of NFE2L2 protein procyanidin B2 inhibits the reaction [Carrageenan affects the localization of NFE2L2 protein] |
CTD |
PMID:28844677 |
|
NCBI chr 3:62,497,568...62,525,146
Ensembl chr 3:62,497,571...62,524,996
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions |
ISO |
NFKBIA protein inhibits the reaction [Carrageenan results in increased expression of EGR1 protein] |
CTD |
PMID:22561171 |
|
NCBI chr 6:76,267,227...76,270,457
Ensembl chr 6:76,267,228...76,270,457
|
|
G |
Ngf |
nerve growth factor |
increases expression multiple interactions |
EXP |
Carrageenan results in increased expression of NGF protein Dexamethasone inhibits the reaction [Carrageenan results in increased expression of NGF protein] |
CTD |
PMID:10653021 |
|
NCBI chr 2:204,886,158...204,939,523
Ensembl chr 2:204,886,202...204,940,453
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions increases expression increases activity |
EXP ISO |
adelmidrol inhibits the reaction [Carrageenan results in increased expression of NOS2 protein]; Carrageenan inhibits the reaction [Raloxifene Hydrochloride results in increased expression of NOS2 protein]; Carrageenan promotes the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]; Dexamethasone inhibits the reaction [Carrageenan results in increased expression of NOS2 mRNA]; Dexamethasone inhibits the reaction [Carrageenan results in increased expression of NOS2 protein]; Fluvoxamine inhibits the reaction [Carrageenan results in increased expression of NOS2 mRNA] fucoxanthin inhibits the reaction [Carrageenan results in increased expression of NOS2 protein]; Indomethacin inhibits the reaction [Carrageenan results in increased expression of NOS2 protein] Carrageenan results in increased activity of NOS2 protein Carrageenan results in increased expression of NOS2 mRNA; Carrageenan results in increased expression of NOS2 protein |
CTD |
PMID:7542281 PMID:9890637 PMID:15860553 PMID:18429935 PMID:22330755 PMID:26418808 PMID:27803785 |
|
NCBI chr10:66,188,290...66,221,621
Ensembl chr10:66,189,786...66,313,190
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
decreases expression multiple interactions |
EXP |
Carrageenan results in decreased expression of NQO1 protein procyanidin B2 inhibits the reaction [Carrageenan results in decreased expression of NQO1 protein] |
CTD |
PMID:28844677 |
|
NCBI chr19:38,422,210...38,437,103
Ensembl chr19:38,422,164...38,437,180
|
|
G |
Oprm1 |
opioid receptor, mu 1 |
decreases expression |
ISO |
Carrageenan results in decreased expression of OPRM1 protein |
CTD |
PMID:30763598 |
|
NCBI chr 1:43,454,803...43,704,948
Ensembl chr 1:43,454,803...43,704,948
|
|
G |
P2rx7 |
purinergic receptor P2X 7 |
multiple interactions |
EXP |
[(N-(1-(((cyanoimino)(5-quinolinylamino) methyl) amino)-2,2-dimethylpropyl)-2-(3,4-dimethoxyphenyl)acetamide) binds to and results in decreased activity of P2RX7 protein] which results in decreased susceptibility to Carrageenan |
CTD |
PMID:16982702 |
|
NCBI chr12:39,353,613...39,396,042
Ensembl chr12:39,353,613...39,396,042
|
|
G |
Pecam1 |
platelet and endothelial cell adhesion molecule 1 |
increases expression multiple interactions |
EXP |
Carrageenan results in increased expression of PECAM1 protein adelmidrol inhibits the reaction [Carrageenan results in increased expression of PECAM1 protein] |
CTD |
PMID:18429935 |
|
NCBI chr10:94,850,971...94,913,202
|
|
G |
Ptges |
prostaglandin E synthase |
multiple interactions increases expression |
EXP |
arvelexin analog inhibits the reaction [Carrageenan results in increased expression of PTGES protein] |
CTD |
PMID:17258197 PMID:25451575 |
|
NCBI chr 3:9,727,408...9,738,752
Ensembl chr 3:9,727,408...9,738,752
|
|
G |
Ptges2 |
prostaglandin E synthase 2 |
multiple interactions increases activity |
EXP |
2-(4-chloro-6-(2,3-dimethylphenylamino)pyrimidin-2-ylthio)octanoic acid inhibits the reaction [[Carrageenan results in increased activity of PTGES2 protein] which results in increased chemical synthesis of Dinoprostone]; [Carrageenan results in increased activity of PTGES2 protein] which results in increased chemical synthesis of Dinoprostone |
CTD |
PMID:19934399 |
|
NCBI chr 3:11,424,195...11,431,379
Ensembl chr 3:11,424,099...11,431,402
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions increases expression |
EXP ISO |
3-methylquercetin inhibits the reaction [Carrageenan results in increased expression of PTGS2 protein]; Carrageenan inhibits the reaction [Raloxifene Hydrochloride results in increased expression of PTGS2 protein]; Dexamethasone inhibits the reaction [Carrageenan results in increased expression of PTGS2 mRNA]; dragon's blood inhibits the reaction [Carrageenan results in increased expression of PTGS2 protein]; Fluvoxamine inhibits the reaction [Carrageenan results in increased expression of PTGS2 mRNA]; isoquercitrin inhibits the reaction [Carrageenan results in increased expression of PTGS2 mRNA]; Ketorolac inhibits the reaction [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide promotes the reaction [Carrageenan results in increased expression of PTGS2 protein]]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide promotes the reaction [Carrageenan results in increased expression of PTGS2 protein]; nimesulide promotes the reaction [Carrageenan results in increased expression of PTGS2 protein]; Quercetin inhibits the reaction [Carrageenan results in increased expression of PTGS2 mRNA]; resveratrol inhibits the reaction [Carrageenan results in increased expression of PTGS2 mRNA]; Thioctic Acid inhibits the reaction [Carrageenan results in increased expression of PTGS2 mRNA]; triflusal inhibits the reaction [Carrageenan results in increased expression of PTGS2 protein] fucoxanthin inhibits the reaction [Carrageenan results in increased expression of PTGS2 protein]; Indomethacin inhibits the reaction [Carrageenan results in increased expression of PTGS2 protein] Carrageenan results in increased expression of PTGS2 mRNA; Carrageenan results in increased expression of PTGS2 protein |
CTD |
PMID:10101034 PMID:14654164 PMID:15860553 PMID:17258197 PMID:18814970 PMID:19735303 PMID:22198006 PMID:24337631 PMID:26418808 PMID:27803785 |
|
NCBI chr13:67,351,230...67,356,920
Ensembl chr13:67,351,087...67,359,335
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
increases phosphorylation increases localization multiple interactions |
ISO EXP |
Carrageenan results in increased phosphorylation of RELA protein Carrageenan results in increased localization of RELA protein IMMLG5521 inhibits the reaction [Carrageenan results in increased localization of RELA protein] |
CTD |
PMID:21549112 PMID:22561171 |
|
NCBI chr 1:220,992,770...221,003,249
Ensembl chr 1:220,992,770...221,003,249
|
|
G |
Selp |
selectin P |
increases expression multiple interactions |
EXP ISO |
Carrageenan results in increased expression of SELP protein IL1R1 protein promotes the reaction [Carrageenan results in increased expression of SELP protein]; PEGylated soluble tumor necrosis factor receptor I inhibits the reaction [Carrageenan results in increased expression of SELP protein]; TNFSF8 protein promotes the reaction [Carrageenan results in increased expression of SELP protein] imisopasem manganese inhibits the reaction [Carrageenan results in increased expression of SELP protein] |
CTD |
PMID:11181422 PMID:15380531 |
|
NCBI chr13:82,428,914...82,464,629
Ensembl chr13:82,429,063...82,464,628
|
|
G |
Sstr4 |
somatostatin receptor 4 |
decreases response to substance |
ISO |
SSTR4 results in decreased susceptibility to Carrageenan |
CTD |
PMID:19622729 |
|
NCBI chr 3:142,739,781...142,741,644
Ensembl chr 3:142,739,781...142,741,644
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
increases secretion |
ISO |
Carrageenan results in increased secretion of TGFB1 protein |
CTD |
PMID:16368644 |
|
NCBI chr 1:82,480,875...82,497,196
Ensembl chr 1:82,480,195...82,497,199
|
|
G |
Tjp1 |
tight junction protein 1 |
multiple interactions |
ISO |
3-(4-methylphenylsulfonyl)-2-propenenitrile promotes the reaction [Carrageenan results in decreased expression of and affects the localization of TJP1 protein]; Carrageenan results in decreased expression of and affects the localization of TJP1 protein; EGR1 protein inhibits the reaction [Carrageenan results in decreased expression of and affects the localization of TJP1 protein] |
CTD |
PMID:22561171 |
|
NCBI chr 1:126,146,489...126,515,359
Ensembl chr 1:126,146,489...126,227,469
|
|
G |
Tnf |
tumor necrosis factor |
increases secretion multiple interactions increases expression |
ISO EXP |
Carrageenan results in increased secretion of TNF protein 3-methylquercetin inhibits the reaction [Carrageenan results in increased expression of TNF protein]; adelmidrol inhibits the reaction [Carrageenan results in increased expression of TNF protein]; budlein A inhibits the reaction [Carrageenan results in increased secretion of TNF protein]; Dexamethasone inhibits the reaction [Carrageenan results in increased expression of TNF protein]; imisopasem manganese inhibits the reaction [Carrageenan results in increased expression of TNF protein]; IMMLG5521 inhibits the reaction [Carrageenan results in increased secretion of TNF protein]; isoquercitrin inhibits the reaction [Carrageenan results in increased expression of TNF protein]; N-(2-hydroxybenzoyl)tyramine inhibits the reaction [Carrageenan results in increased expression of TNF protein]; procyanidin B2 inhibits the reaction [Carrageenan results in increased expression of TNF protein]; Quercetin inhibits the reaction [Carrageenan results in increased expression of TNF protein]; Rutin inhibits the reaction [Carrageenan results in increased expression of TNF protein]; Thiazolidines analog inhibits the reaction [Carrageenan results in increased expression of TNF protein] 5S,12R,18R-trihydroxy-6Z,8E,10E,14Z,16E-eicosapentaenoic acid inhibits the reaction [Carrageenan results in increased expression of TNF protein]; IL1R1 protein promotes the reaction [Carrageenan results in increased expression of TNF protein]; indole-3-guanylhydrazone hydrochloride inhibits the reaction [Carrageenan results in increased secretion of TNF protein]; Indomethacin inhibits the reaction [Carrageenan results in increased secretion of TNF protein]; PEGylated soluble tumor necrosis factor receptor I inhibits the reaction [Carrageenan results in increased expression of TNF protein]; TNFSF8 protein promotes the reaction [Carrageenan results in increased expression of TNF protein] |
CTD |
PMID:11181422 PMID:12444156 PMID:14654164 PMID:15380531 PMID:16368644 PMID:17320857 PMID:18429935 PMID:20383154 PMID:21549112 PMID:22330755 PMID:23774260 PMID:23872256 PMID:24412305 PMID:28844677 PMID:29499192 |
|
NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
|
|
G |
Tnfrsf8 |
TNF receptor superfamily member 8 |
multiple interactions increases expression |
ISO |
IL1R1 protein promotes the reaction [Carrageenan results in increased expression of TNFRSF8 protein]; TNFSF8 protein promotes the reaction [Carrageenan results in increased expression of TNFRSF8 protein] |
CTD |
PMID:15380531 |
|
NCBI chr 5:163,186,349...163,231,578
Ensembl chr 5:163,186,349...163,231,578
|
|
G |
Tnfsf8 |
TNF superfamily member 8 |
increases expression multiple interactions increases response to substance |
ISO |
Carrageenan results in increased expression of TNFSF8 protein IL1R1 protein promotes the reaction [Carrageenan results in increased expression of TNFSF8 protein]; TNFSF8 protein promotes the reaction [Carrageenan results in increased expression of ICAM1 protein]; TNFSF8 protein promotes the reaction [Carrageenan results in increased expression of SELP protein]; TNFSF8 protein promotes the reaction [Carrageenan results in increased expression of TNF protein]; TNFSF8 protein promotes the reaction [Carrageenan results in increased expression of TNFRSF8 protein]; TNFSF8 protein promotes the reaction [Carrageenan results in increased expression of TNFSF8 protein] TNFSF8 protein results in increased susceptibility to Carrageenan |
CTD |
PMID:15380531 |
|
NCBI chr 5:79,664,779...79,691,547
Ensembl chr 5:79,664,765...79,691,258
|
|
G |
Vcam1 |
vascular cell adhesion molecule 1 |
increases expression multiple interactions |
EXP |
Carrageenan results in increased expression of VCAM1 mRNA Dexamethasone inhibits the reaction [Carrageenan results in increased expression of VCAM1 mRNA]; Fluvoxamine inhibits the reaction [Carrageenan results in increased expression of VCAM1 mRNA] |
CTD |
PMID:27803785 |
|
NCBI chr 2:219,071,193...219,090,931
Ensembl chr 2:219,071,193...219,097,619
|
|
|
G |
Il10 |
interleukin 10 |
multiple interactions |
ISO |
[Dextrans co-treated with ferrite analog] results in increased expression of IL10 mRNA |
CTD |
PMID:26576301 |
|
NCBI chr13:47,738,933...47,743,392
Ensembl chr13:47,739,526...47,743,392
|
|
G |
Irak1 |
interleukin-1 receptor-associated kinase 1 |
multiple interactions |
ISO |
[Dextrans co-treated with ferrite analog] results in decreased expression of IRAK1 mRNA |
CTD |
PMID:26576301 |
|
NCBI chr X:156,716,469...156,726,367
Ensembl chr X:156,716,604...156,725,977
|
|
G |
Slc31a2 |
solute carrier family 31 member 2 |
decreases uptake |
ISO |
SLC31A2 protein results in decreased uptake of Dextrans |
CTD |
PMID:20930109 |
|
NCBI chr 5:78,120,606...78,131,111
Ensembl chr 5:78,120,607...78,131,114
|
|
G |
Tnfrsf1b |
TNF receptor superfamily member 1B |
multiple interactions |
ISO |
[Dextrans co-treated with ferrite analog] results in decreased expression of TNFRSF1B mRNA |
CTD |
PMID:26576301 |
|
NCBI chr 5:163,136,390...163,167,299
Ensembl chr 5:163,136,390...163,167,299
|
|
|
G |
Abat |
4-aminobutyrate aminotransferase |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ABAT mRNA |
CTD |
PMID:29950665 |
|
NCBI chr10:7,093,406...7,200,439
Ensembl chr10:7,093,405...7,200,499
|
|
G |
Abca1 |
ATP binding cassette subfamily A member 1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ABCA1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 5:69,857,717...69,983,042
Ensembl chr 5:69,857,771...69,983,015
|
|
G |
Abcb11 |
ATP binding cassette subfamily B member 11 |
decreases expression |
ISO |
Dextran Sulfate results in decreased expression of ABCB11 mRNA; Dextran Sulfate results in decreased expression of ABCB11 protein |
CTD |
PMID:27580383 |
|
NCBI chr 3:55,480,024...55,587,946
Ensembl chr 3:55,480,024...55,587,946
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ABCB1A mRNA; ABCB1A protein affects the susceptibility to [Dextran Sulfate co-treated with 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine] |
CTD |
PMID:29950665 PMID:30701287 |
|
NCBI chr 4:22,339,829...22,517,642
Ensembl chr 4:22,133,521...22,425,515
|
|
G |
Abcb1b |
ATP-binding cassette, subfamily B (MDR/TAP), member 1B |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ABCB1B mRNA; ABCB1B protein affects the susceptibility to [Dextran Sulfate co-treated with 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine] |
CTD |
PMID:29950665 PMID:30701287 |
|
NCBI chr 4:22,225,123...22,307,577
Ensembl chr 4:22,133,521...22,425,515
|
|
G |
Abcb4 |
ATP binding cassette subfamily B member 4 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ABCB4 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 4:22,133,984...22,192,687
Ensembl chr 4:22,133,521...22,425,515
|
|
G |
Abcb6 |
ATP binding cassette subfamily B member 6 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ABCB6 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 9:82,373,950...82,382,228
Ensembl chr 9:82,373,946...82,382,272
|
|
G |
Abcc10 |
ATP binding cassette subfamily C member 10 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ABCC10 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 9:17,041,351...17,061,263
Ensembl chr 9:17,041,389...17,063,780
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
decreases expression multiple interactions affects response to substance |
ISO |
Dextran Sulfate results in decreased expression of ABCC2 mRNA; Dextran Sulfate results in decreased expression of ABCC2 protein ABCC2 protein affects the susceptibility to [Dextran Sulfate co-treated with 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine] ABCC2 protein affects the susceptibility to Dextran Sulfate |
CTD |
PMID:27580383 PMID:30701287 |
|
NCBI chr 1:263,554,426...263,612,556
Ensembl chr 1:263,554,453...263,613,252
|
|
G |
Abcc3 |
ATP binding cassette subfamily C member 3 |
decreases expression affects response to substance multiple interactions |
ISO |
Dextran Sulfate results in decreased expression of ABCC3 mRNA; Dextran Sulfate results in decreased expression of ABCC3 protein ABCC3 protein affects the susceptibility to Dextran Sulfate [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ABCC3 mRNA; ABCC3 protein affects the susceptibility to [Dextran Sulfate co-treated with 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine] |
CTD |
PMID:27580383 PMID:29950665 PMID:30701287 |
|
NCBI chr10:82,047,308...82,116,928
Ensembl chr10:82,047,863...82,117,109
|
|
G |
Abcc4 |
ATP binding cassette subfamily C member 4 |
multiple interactions decreases expression |
ISO |
[Benzo(a)pyrene co-treated with Dextran Sulfate] results in increased expression of ABCC4 mRNA; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ABCC4 mRNA Dextran Sulfate results in decreased expression of ABCC4 mRNA; Dextran Sulfate results in decreased expression of ABCC4 protein |
CTD |
PMID:26271895 PMID:27580383 PMID:29950665 |
|
NCBI chr15:103,695,415...103,927,980
Ensembl chr15:103,696,557...103,927,592
|
|
G |
Abcc5 |
ATP binding cassette subfamily C member 5 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ABCC5 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr11:84,395,982...84,490,215
Ensembl chr11:84,396,033...84,490,211
|
|
G |
Abcc6 |
ATP binding cassette subfamily C member 6 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ABCC6 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 1:101,954,786...102,013,252
Ensembl chr 1:101,959,540...102,013,243
|
|
G |
Abcc9 |
ATP binding cassette subfamily C member 9 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ABCC9 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 4:176,806,098...176,928,540
Ensembl chr 4:176,805,431...176,922,424
|
|
G |
Abcf2 |
ATP binding cassette subfamily F member 2 |
decreases expression multiple interactions |
ISO |
Dextran Sulfate results in decreased expression of ABCF2 protein Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of ABCF2 protein] |
CTD |
PMID:32272095 |
|
NCBI chr 4:7,122,850...7,135,607
Ensembl chr 4:7,122,890...7,135,669
|
|
G |
Abcg1 |
ATP binding cassette subfamily G member 1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ABCG1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr20:9,743,269...9,842,735
Ensembl chr20:9,743,269...9,840,489
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 |
multiple interactions affects response to substance |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ABCG2 mRNA; ABCG2 protein affects the susceptibility to [Dextran Sulfate co-treated with 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine] ABCG2 protein affects the susceptibility to Dextran Sulfate |
CTD |
PMID:29950665 PMID:30701287 |
|
NCBI chr 4:88,765,441...88,890,268
Ensembl chr 4:88,832,178...88,890,621
|
|
G |
Abi1 |
abl-interactor 1 |
multiple interactions decreases expression |
ISO |
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of ABI1 protein] |
CTD |
PMID:32272095 |
|
NCBI chr17:89,951,662...90,033,334
Ensembl chr17:89,951,752...90,033,328
|
|
G |
Acaa1a |
acetyl-CoA acyltransferase 1A |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ACAA1A mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 8:128,027,880...128,036,471
Ensembl chr 8:128,027,958...128,036,236
|
|
G |
Acaa1b |
acetyl-Coenzyme A acyltransferase 1B |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ACAA1B mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 8:127,836,235...127,845,296
|
|
G |
Acaa2 |
acetyl-CoA acyltransferase 2 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ACAA2 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr18:70,733,872...70,762,395
Ensembl chr18:70,733,872...70,762,395
|
|
G |
Acaca |
acetyl-CoA carboxylase alpha |
multiple interactions increases expression |
ISO |
Erianin inhibits the reaction [Dextran Sulfate results in increased expression of ACACA protein] |
CTD |
PMID:32272095 |
|
NCBI chr10:71,519,392...71,719,910
Ensembl chr10:71,536,533...71,719,910
|
|
G |
Acads |
acyl-CoA dehydrogenase short chain |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ACADS mRNA |
CTD |
PMID:29950665 |
|
NCBI chr12:47,254,503...47,263,747
Ensembl chr12:47,254,484...47,263,747
|
|
G |
Acadsb |
acyl-CoA dehydrogenase, short/branched chain |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ACADSB mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 1:201,981,362...202,022,771
Ensembl chr 1:201,981,357...202,021,008
|
|
G |
Ace |
angiotensin I converting enzyme |
multiple interactions increases abundance |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ACE mRNA dextran sodium sulfate increases abundance of Ace protein in small and large intestine extracellular space |
CTD |
PMID:29950665, PMID:26401072 |
RGD:11555935 |
NCBI chr10:94,170,766...94,213,831
Ensembl chr10:94,170,766...94,187,822
|
|
G |
Ache |
acetylcholinesterase |
multiple interactions decreases activity |
ISO |
[Chlorpyrifos co-treated with Dextran Sulfate] results in decreased activity of ACHE protein; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ACHE mRNA Dextran Sulfate results in decreased activity of ACHE protein |
CTD |
PMID:29950665 PMID:31226429 PMID:31807802 |
|
NCBI chr12:22,472,358...22,477,052
Ensembl chr12:22,472,358...22,478,753
|
|
G |
Ackr1 |
atypical chemokine receptor 1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ACKR1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr13:91,827,310...91,828,875
|
|
G |
Ackr2 |
atypical chemokine receptor 2 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ACKR2 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 8:130,526,521...130,543,566
Ensembl chr 8:130,538,651...130,542,227
|
|
G |
Ackr3 |
atypical chemokine receptor 3 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ACKR3 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 9:97,355,881...97,367,455
Ensembl chr 9:97,355,924...97,367,445
|
|
G |
Ackr4 |
atypical chemokine receptor 4 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ACKR4 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 8:112,643,838...112,651,668
Ensembl chr 8:112,644,222...112,648,880
|
|
G |
Acsbg2 |
acyl-CoA synthetase bubblegum family member 2 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ACSBG2 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 9:10,172,317...10,203,550
Ensembl chr 9:10,172,832...10,203,460
|
|
G |
Acsm1 |
acyl-CoA synthetase medium-chain family member 1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ACSM1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 1:189,359,374...189,395,277
Ensembl chr 1:189,289,957...189,395,276
|
|
G |
Acsm3 |
acyl-CoA synthetase medium-chain family member 3 |
decreases expression multiple interactions |
ISO |
Dextran Sulfate results in decreased expression of ACSM3 protein Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of ACSM3 protein] |
CTD |
PMID:32272095 |
|
NCBI chr 1:189,514,504...189,541,233
Ensembl chr 1:189,514,553...189,541,224
|
|
G |
Acss1 |
acyl-CoA synthetase short-chain family member 1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ACSS1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 3:146,420,346...146,470,293
Ensembl chr 3:146,420,346...146,470,293
|
|
G |
Acss2 |
acyl-CoA synthetase short-chain family member 2 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ACSS2 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 3:151,032,925...151,075,856
Ensembl chr 3:151,032,952...151,075,856
|
|
G |
Actl6a |
actin-like 6A |
multiple interactions decreases expression |
ISO |
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of ACTL6A protein] |
CTD |
PMID:32272095 |
|
NCBI chr 2:119,112,776...119,128,870
Ensembl chr 2:119,112,513...119,129,751
|
|
G |
Actn1 |
actinin, alpha 1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ACTN1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 6:103,376,557...103,470,497
Ensembl chr 6:103,375,799...103,470,555
|
|
G |
Actn2 |
actinin alpha 2 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ACTN2 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr17:66,304,530...66,397,647
Ensembl chr17:66,304,501...66,397,653
|
|
G |
Acvr1 |
activin A receptor type 1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ACVR1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 3:44,432,476...44,539,680
Ensembl chr 3:44,432,471...44,522,930
|
|
G |
Ada |
adenosine deaminase |
increases expression multiple interactions |
ISO |
Dextran Sulfate results in increased expression of ADA protein Erianin inhibits the reaction [Dextran Sulfate results in increased expression of ADA protein] |
CTD |
PMID:32272095 |
|
NCBI chr 3:160,115,840...160,139,947
Ensembl chr 3:160,115,842...160,139,947
|
|
G |
Adam17 |
ADAM metallopeptidase domain 17 |
multiple interactions increases expression affects response to substance |
ISO |
ADAM17 protein affects the reaction [Dextran Sulfate results in decreased expression of SIRT1 mRNA]; ADAM17 protein affects the reaction [Dextran Sulfate results in decreased expression of TIMP3 mRNA]; ADAM17 protein affects the reaction [Dextran Sulfate results in increased expression of IFNG protein]; ADAM17 protein affects the reaction [Dextran Sulfate results in increased expression of IL17A protein]; ADAM17 protein affects the reaction [Dextran Sulfate results in increased expression of IL1B protein]; ADAM17 protein affects the reaction [Dextran Sulfate results in increased expression of IL6 protein]; ADAM17 protein affects the reaction [Dextran Sulfate results in increased expression of TNF protein]; resveratrol inhibits the reaction [Dextran Sulfate results in increased expression of ADAM17 mRNA] ADAM17 protein affects the susceptibility to Dextran Sulfate |
CTD |
PMID:24548422 |
|
NCBI chr 6:43,400,525...43,448,280
Ensembl chr 6:43,400,528...43,448,280
|
|
G |
Adamts1 |
ADAM metallopeptidase with thrombospondin type 1 motif, 1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADAMTS1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr11:25,342,119...25,350,938
Ensembl chr11:25,342,126...25,350,974
|
|
G |
Adamts14 |
ADAM metallopeptidase with thrombospondin type 1 motif, 14 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADAMTS14 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr20:30,812,319...30,888,936
Ensembl chr20:30,812,353...30,888,751
|
|
G |
Adamts2 |
ADAM metallopeptidase with thrombospondin type 1 motif, 2 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADAMTS2 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr10:36,098,051...36,304,416
Ensembl chr10:36,098,051...36,304,409
|
|
G |
Adamts4 |
ADAM metallopeptidase with thrombospondin type 1 motif, 4 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADAMTS4 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr13:89,622,996...89,632,485
Ensembl chr13:89,622,632...89,634,419
|
|
G |
Adamts5 |
ADAM metallopeptidase with thrombospondin type 1 motif, 5 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADAMTS5 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr11:25,411,174...25,456,639
Ensembl chr11:25,410,975...25,456,836
|
|
G |
Adcy2 |
adenylate cyclase 2 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADCY2 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 1:37,043,071...37,698,390
Ensembl chr 1:37,507,276...37,698,390
|
|
G |
Adcy4 |
adenylate cyclase 4 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADCY4 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr15:34,453,917...34,469,779
Ensembl chr15:34,453,915...34,469,746
|
|
G |
Adcy6 |
adenylate cyclase 6 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ADCY6 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 7:140,270,678...140,291,722
Ensembl chr 7:140,270,692...140,291,620
|
|
G |
Adcy7 |
adenylate cyclase 7 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADCY7 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr19:19,702,307...19,762,973
Ensembl chr19:19,704,859...19,727,081
|
|
G |
Adcyap1 |
adenylate cyclase activating polypeptide 1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADCYAP1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 9:121,705,897...121,725,736
Ensembl chr 9:121,706,979...121,725,716
|
|
G |
Adcyap1r1 |
ADCYAP receptor type I |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ADCYAP1R1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 4:85,662,809...85,711,696
Ensembl chr 4:85,662,892...85,711,696
|
|
G |
Adgra2 |
adhesion G protein-coupled receptor A2 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADGRA2 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr16:69,094,587...69,133,015
Ensembl chr16:69,095,936...69,132,584
|
|
G |
Adgrb1 |
adhesion G protein-coupled receptor B1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ADGRB1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 7:115,766,484...115,828,514
|
|
G |
Adgre5 |
adhesion G protein-coupled receptor E5 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADGRE5 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr19:24,854,981...24,875,712
Ensembl chr19:24,855,299...24,875,137
|
|
G |
Adgrf1 |
adhesion G protein-coupled receptor F1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADGRF1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 9:20,343,730...20,378,686
|
|
G |
Adgrf5 |
adhesion G protein-coupled receptor F5 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADGRF5 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 9:20,091,121...20,195,706
Ensembl chr 9:20,091,099...20,195,566
|
|
G |
Adh1 |
alcohol dehydrogenase 1 (class I) |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADH1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 2:243,550,655...243,562,243
Ensembl chr 2:243,550,627...243,687,857
|
|
G |
Adh5 |
alcohol dehydrogenase 5 (class III), chi polypeptide |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ADH5 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 2:243,728,500...243,740,907
Ensembl chr 2:243,700,784...243,740,899
|
|
G |
Adm |
adrenomedullin |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADM mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 1:175,443,189...175,447,260
Ensembl chr 1:175,445,088...175,447,259
|
|
G |
Adora2a |
adenosine A2a receptor |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADORA2A mRNA |
CTD |
PMID:29950665 |
|
NCBI chr20:14,265,251...14,282,873
Ensembl chr20:14,265,252...14,282,873
|
|
G |
Adora2b |
adenosine A2B receptor |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] affects the expression of ADORA2B mRNA |
CTD |
PMID:29950665 |
|
NCBI chr10:48,569,563...48,586,366
Ensembl chr10:48,569,555...48,586,365
|
|
G |
Adora3 |
adenosine A3 receptor |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADORA3 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 2:208,336,909...208,379,217
Ensembl chr 2:208,373,154...208,376,803
|
|
G |
Adra2a |
adrenoceptor alpha 2A |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ADRA2A mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 1:274,766,283...274,769,083
Ensembl chr 1:274,766,283...274,769,081
|
|
G |
Adrb2 |
adrenoceptor beta 2 |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with Dextran Sulfate] results in increased expression of ADRB2 mRNA; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADRB2 mRNA |
CTD |
PMID:26271895 PMID:29950665 |
|
NCBI chr18:57,513,792...57,515,834
Ensembl chr18:57,513,793...57,515,834
|
|
G |
Agt |
angiotensinogen |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of AGT mRNA |
CTD |
PMID:29950665 |
|
NCBI chr19:57,321,594...57,333,460
Ensembl chr19:57,321,640...57,333,433
|
|
G |
Akap12 |
A-kinase anchoring protein 12 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of AKAP12 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 1:40,816,130...40,906,582
Ensembl chr 1:40,816,107...40,906,581
|
|
G |
Akap5 |
A-kinase anchoring protein 5 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of AKAP5 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 6:99,356,509...99,361,909
Ensembl chr 6:99,356,509...99,361,909
|
|
G |
Akr1b1 |
aldo-keto reductase family 1 member B |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of AKR1B3 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 4:61,706,866...61,720,959
Ensembl chr 4:61,706,864...61,720,956
|
|
G |
Akr1c3 |
aldo-keto reductase family 1, member C3 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of AKR1C18 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr17:69,761,126...69,778,021
Ensembl chr17:69,761,118...69,778,021
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions |
ISO |
[APC protein affects the susceptibility to Dextran Sulfate] which results in increased phosphorylation of AKT1 protein; resorcinol inhibits the reaction [[APC protein affects the susceptibility to Dextran Sulfate] which results in increased phosphorylation of AKT1 protein] |
CTD |
PMID:26262998 |
|
NCBI chr 6:137,218,398...137,239,970
Ensembl chr 6:137,218,376...137,236,258
|
|
G |
Alb |
albumin |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ALB mRNA |
CTD |
PMID:29950665 |
|
NCBI chr14:19,176,275...19,191,793
Ensembl chr14:19,176,277...19,191,863
|
|
G |
Aldh1a1 |
aldehyde dehydrogenase 1 family, member A1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ALDH1A1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 1:238,222,689...238,264,381
Ensembl chr 1:238,222,521...238,264,330
|
|
G |
Aldh1b1 |
aldehyde dehydrogenase 1 family, member B1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ALDH1B1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 5:61,382,351...61,387,359
Ensembl chr 5:61,382,351...61,387,358
|
|
G |
Aldh2 |
aldehyde dehydrogenase 2 family member |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ALDH2 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr12:40,466,418...40,498,813
Ensembl chr12:40,466,495...40,498,752
|
|
G |
Aldh3a2 |
aldehyde dehydrogenase 3 family, member A2 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ALDH3A2 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr10:47,525,486...47,546,535
Ensembl chr10:47,525,493...47,546,345
|
|
G |
Aldh7a1 |
aldehyde dehydrogenase 7 family, member A1 |
multiple interactions increases expression |
ISO |
Erianin inhibits the reaction [Dextran Sulfate results in increased expression of ALDH7A1 protein] |
CTD |
PMID:32272095 |
|
NCBI chr18:51,619,007...51,651,267
Ensembl chr18:51,619,007...51,651,267
|
|
G |
Alox12b |
arachidonate 12-lipoxygenase, 12R type |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ALOX12B mRNA |
CTD |
PMID:29950665 |
|
NCBI chr10:55,744,646...55,756,524
Ensembl chr10:55,744,588...55,756,566
|
|
G |
Alox5 |
arachidonate 5-lipoxygenase |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ALOX5 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 4:148,398,004...148,446,308
Ensembl chr 4:148,398,892...148,446,303
|
|
G |
Alox5ap |
arachidonate 5-lipoxygenase activating protein |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ALOX5AP mRNA |
CTD |
PMID:29950665 |
|
NCBI chr12:6,854,930...6,879,112
Ensembl chr12:6,854,920...6,879,154
|
|
G |
Alpl |
alkaline phosphatase, biomineralization associated |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ALPL mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 5:156,086,496...156,141,513
Ensembl chr 5:156,086,497...156,141,537
|
|
G |
Angpt4 |
angiopoietin 4 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ANGPT4 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 3:147,421,724...147,455,670
Ensembl chr 3:147,422,095...147,455,670
|
|
G |
Ano1 |
anoctamin 1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ANO1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 1:217,754,349...217,902,540
Ensembl chr 1:217,754,336...217,902,473
|
|
G |
Ano10 |
anoctamin 10 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ANO10 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 8:130,812,941...130,931,021
Ensembl chr 8:130,813,214...130,930,990
|
|
G |
Ano6 |
anoctamin 6 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ANO6 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 7:137,142,063...137,335,208
Ensembl chr 7:137,142,170...137,335,208
|
|
G |
Ano7 |
anoctamin 7 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ANO7 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 9:100,511,610...100,551,798
Ensembl chr 9:100,511,610...100,551,798
|
|
G |
Ano9 |
anoctamin 9 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ANO9 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 1:213,908,389...213,929,291
Ensembl chr 1:213,908,982...213,921,208
|
|
G |
Anos1 |
anosmin 1 |
increases expression |
ISO |
Dextran Sulfate results in increased expression of WFDC17 mRNA |
CTD |
PMID:23894361 |
|
Ensembl chr10:70,999,780...71,000,627
|
|
G |
Anxa1 |
annexin A1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ANXA1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 1:237,893,983...237,910,002
Ensembl chr 1:237,893,966...237,910,012
|
|
G |
Anxa4 |
annexin A4 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ANXA4 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 4:118,538,775...118,595,591
Ensembl chr 4:118,538,777...118,595,580
|
|
G |
Ap1m1 |
adaptor related protein complex 1 subunit mu 1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of AP1M1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr16:19,288,354...19,303,818
Ensembl chr16:19,288,355...19,303,824
|
|
G |
Ap1s1 |
adaptor related protein complex 1 subunit sigma 1 |
decreases expression multiple interactions |
ISO |
Dextran Sulfate results in decreased expression of AP1S1 protein Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of AP1S1 protein] |
CTD |
PMID:32272095 |
|
NCBI chr12:22,665,128...22,676,079
Ensembl chr12:22,665,112...22,676,075
|
|
G |
Apc |
APC regulator of WNT signaling pathway |
affects response to substance multiple interactions |
ISO |
APC affects the susceptibility to Dextran Sulfate; APC protein affects the susceptibility to Dextran Sulfate [APC protein affects the susceptibility to Dextran Sulfate] which affects the activity of MPO protein; [APC protein affects the susceptibility to Dextran Sulfate] which results in increased chemical synthesis of PTEN protein modified form; [APC protein affects the susceptibility to Dextran Sulfate] which results in increased phosphorylation of AKT1 protein; PDE4B protein affects the reaction [APC protein affects the susceptibility to Dextran Sulfate]; resorcinol inhibits the reaction [[APC protein affects the susceptibility to Dextran Sulfate] which affects the activity of MPO protein]; resorcinol inhibits the reaction [[APC protein affects the susceptibility to Dextran Sulfate] which results in increased chemical synthesis of PTEN protein modified form]; resorcinol inhibits the reaction [[APC protein affects the susceptibility to Dextran Sulfate] which results in increased phosphorylation of AKT1 protein] |
CTD |
PMID:16049979 PMID:26262998 PMID:30188895 |
|
NCBI chr18:27,011,710...27,106,323
Ensembl chr18:27,047,382...27,105,531
|
|
G |
Apln |
apelin |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of APLN mRNA |
CTD |
PMID:29950665 |
|
NCBI chr X:134,856,719...134,866,210
Ensembl chr X:134,856,726...134,866,210
|
|
G |
Apoa4 |
apolipoprotein A4 |
decreases expression multiple interactions |
ISO |
Dextran Sulfate results in decreased expression of APOA4 protein Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of APOA4 protein] |
CTD |
PMID:32272095 |
|
NCBI chr 8:50,536,983...50,539,371
Ensembl chr 8:50,537,009...50,539,376
|
|
G |
Apob |
apolipoprotein B |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of APOB mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 6:33,176,826...33,216,381
Ensembl chr 6:33,176,778...33,224,997
|
|
G |
Apoe |
apolipoprotein E |
increases expression multiple interactions |
ISO |
Dextran Sulfate results in increased expression of APOE protein Erianin inhibits the reaction [Dextran Sulfate results in increased expression of APOE protein] |
CTD |
PMID:32272095 |
|
NCBI chr 1:80,612,894...80,616,820
Ensembl chr 1:80,612,895...80,617,057
|
|
G |
App |
amyloid beta precursor protein |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of APP mRNA |
CTD |
PMID:29950665 |
|
NCBI chr11:24,425,013...24,641,872
Ensembl chr11:24,425,005...24,641,858
|
|
G |
Aqp1 |
aquaporin 1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of AQP1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 4:85,551,503...85,563,683
Ensembl chr 4:85,551,502...85,569,360
|
|
G |
Aqp11 |
aquaporin 11 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of AQP11 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 1:162,703,394...162,713,560
Ensembl chr 1:162,703,442...162,713,610
|
|
G |
Aqp2 |
aquaporin 2 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of AQP2 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 7:141,237,802...141,242,837
Ensembl chr 7:141,237,768...141,245,165
|
|
G |
Aqp3 |
aquaporin 3 (Gill blood group) |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of AQP3 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 5:57,423,735...57,429,252
Ensembl chr 5:57,423,734...57,429,245
|
|
G |
Aqp8 |
aquaporin 8 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of AQP8 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 1:193,424,818...193,430,665
Ensembl chr 1:193,424,812...193,430,676
|
|
G |
Aqp9 |
aquaporin 9 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of AQP9 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 8:77,559,621...77,599,781
Ensembl chr 8:77,559,624...77,599,781
|
|
G |
Ar |
androgen receptor |
multiple interactions increases expression |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of AR mRNA Dextran Sulfate results in increased expression of AR mRNA |
CTD |
PMID:27920257 PMID:29950665 |
|
NCBI chr X:67,656,253...67,828,998
Ensembl chr X:67,656,253...67,829,026
|
|
G |
Arg1 |
arginase 1 |
multiple interactions |
ISO |
[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ARG1 mRNA; [Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ARG1 protein; isoliquiritigenin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ARG1 mRNA]; isoliquiritigenin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ARG1 protein] |
CTD |
PMID:25026504 |
|
NCBI chr 1:21,525,421...21,537,872
Ensembl chr 1:21,525,421...21,537,863
|
|
G |
Arhgap15 |
Rho GTPase activating protein 15 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ARHGAP15 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 3:28,626,987...29,236,225
Ensembl chr 3:28,627,084...29,236,219
|
|
G |
Arhgap20 |
Rho GTPase activating protein 20 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ARHGAP20 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 8:56,179,581...56,264,343
Ensembl chr 8:56,179,637...56,264,263
|
|
G |
Arhgap25 |
Rho GTPase activating protein 25 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ARHGAP25 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 4:119,249,682...119,327,822
Ensembl chr 4:119,249,682...119,327,822
|
|
G |
Arhgap40 |
Rho GTPase activating protein 40 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ARHGAP40 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 3:154,996,685...155,042,199
Ensembl chr 3:154,996,750...155,041,816
|
|
G |
Arhgdib |
Rho GDP dissociation inhibitor beta |
increases expression multiple interactions |
ISO |
Dextran Sulfate results in increased expression of ARHGDIB mRNA [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ARHGDIB mRNA |
CTD |
PMID:23894361 PMID:29950665 |
|
NCBI chr 4:170,913,920...170,932,789
Ensembl chr 4:170,913,923...170,932,618
|
|
G |
Arhgef1 |
Rho guanine nucleotide exchange factor 1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ARHGEF1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 1:81,769,212...81,797,237
Ensembl chr 1:81,779,380...81,797,236
|
|
G |
Arhgef12 |
Rho guanine nucleotide exchange factor 12 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ARHGEF12 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 8:47,259,377...47,393,042
Ensembl chr 8:47,259,404...47,393,503
|
|
G |
Arhgef6 |
Rac/Cdc42 guanine nucleotide exchange factor 6 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ARHGEF6 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr X:159,722,031...159,841,344
Ensembl chr X:159,723,866...159,841,072
|
|
G |
Arrb2 |
arrestin, beta 2 |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with Dextran Sulfate] results in increased expression of ARRB2 mRNA |
CTD |
PMID:26271895 |
|
NCBI chr10:57,040,252...57,048,045
Ensembl chr10:57,040,267...57,048,134
|
|
G |
Asb2 |
ankyrin repeat and SOCS box-containing 2 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ASB2 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 6:127,212,325...127,248,451
Ensembl chr 6:127,212,273...127,248,372
|
|
G |
Asic4 |
acid sensing ion channel subunit family member 4 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ASIC4 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 9:82,647,071...82,668,920
Ensembl chr 9:82,647,071...82,668,920
|
|
G |
Atg5 |
autophagy related 5 |
multiple interactions increases expression |
ISO |
2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [alpinetin promotes the reaction [Dextran Sulfate results in increased expression of ATG5 mRNA]]; 6-formylindolo(3,2-b)carbazole promotes the reaction [Dextran Sulfate results in increased expression of ATG5 mRNA]; alpinetin promotes the reaction [Dextran Sulfate results in increased expression of ATG5 mRNA]; ATG5 protein affects the reaction [HU 308 inhibits the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased cleavage of CASP1 protein]]; ATG5 protein affects the reaction [HU 308 inhibits the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased secretion of IL1B protein]]; Leucine inhibits the reaction [alpinetin promotes the reaction [Dextran Sulfate results in increased expression of ATG5 mRNA]] |
CTD |
PMID:27611972 PMID:31676321 |
|
NCBI chr20:49,301,783...49,393,147
Ensembl chr20:49,318,308...49,393,140
|
|
G |
Atg7 |
autophagy related 7 |
multiple interactions increases expression |
ISO |
2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [alpinetin promotes the reaction [Dextran Sulfate results in increased expression of ATG7 mRNA]]; 6-formylindolo(3,2-b)carbazole promotes the reaction [Dextran Sulfate results in increased expression of ATG7 mRNA]; alpinetin promotes the reaction [Dextran Sulfate results in increased expression of ATG7 mRNA]; Leucine inhibits the reaction [alpinetin promotes the reaction [Dextran Sulfate results in increased expression of ATG7 mRNA]] |
CTD |
PMID:31676321 |
|
NCBI chr 4:146,570,113...146,777,093
Ensembl chr 4:146,598,413...146,777,124
|
|
G |
Atp10a |
ATPase phospholipid transporting 10A (putative) |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ATP10A mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 1:115,973,343...116,141,892
Ensembl chr 1:115,975,324...116,141,892
|
|
G |
Atp11b |
ATPase phospholipid transporting 11B (putative) |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ATP11B mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 2:122,337,757...122,445,090
Ensembl chr 2:122,368,265...122,444,878
|
|
G |
Atp12a |
ATPase H+/K+ transporting non-gastric alpha2 subunit |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ATP12A mRNA |
CTD |
PMID:29950665 |
|
NCBI chr15:36,561,306...36,590,171
Ensembl chr15:36,565,495...36,590,171
|
|
G |
Atp1a1 |
ATPase Na+/K+ transporting subunit alpha 1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ATP1A1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 2:204,003,742...204,032,023
Ensembl chr 2:204,003,742...204,032,023
|
|
G |
Atp1a3 |
ATPase Na+/K+ transporting subunit alpha 3 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ATP1A3 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 1:81,852,423...81,881,565
Ensembl chr 1:81,852,429...81,881,549
|
|
G |
Atp1a4 |
ATPase Na+/K+ transporting subunit alpha 4 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ATP1A4 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr13:90,605,792...90,642,032
Ensembl chr13:90,605,794...90,641,772
|
|
G |
Atp1b1 |
ATPase Na+/K+ transporting subunit beta 1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ATP1B1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr13:82,737,161...82,757,681
Ensembl chr13:82,737,159...82,758,004
|
|
G |
Atp1b3 |
ATPase Na+/K+ transporting subunit beta 3 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ATP1B3 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 8:104,190,032...104,221,342
Ensembl chr 8:104,190,032...104,221,342
|
|
G |
Atp2a1 |
ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ATP2A1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 1:197,855,912...197,875,038
|
|
G |
Atp2a3 |
ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 3 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ATP2A3 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr10:59,528,849...59,560,440
Ensembl chr10:59,529,785...59,560,433
|
|
G |
Atp2b1 |
ATPase plasma membrane Ca2+ transporting 1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ATP2B1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 7:41,114,606...41,223,138
Ensembl chr 7:41,114,697...41,220,579
|
|
G |
Atp2c2 |
ATPase secretory pathway Ca2+ transporting 2 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] affects the expression of ATP2C2 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr19:52,347,480...52,404,608
Ensembl chr19:52,347,580...52,404,607
|
|
G |
Atp4b |
ATPase H+/K+ transporting subunit beta |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ATP4B mRNA |
CTD |
PMID:29950665 |
|
NCBI chr16:81,136,218...81,145,131
Ensembl chr16:81,136,218...81,145,131
|
|
G |
Atp6v0a2 |
ATPase H+ transporting V0 subunit a2 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ATP6V0A2 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr12:37,368,321...37,398,233
Ensembl chr12:37,363,906...37,425,596
|
|
G |
Atp6v0a4 |
ATPase H+ transporting V0 subunit a4 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ATP6V0A4 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 4:65,736,585...65,821,916
Ensembl chr 4:65,736,585...65,818,521
|
|
G |
Atp6v0d2 |
ATPase H+ transporting V0 subunit D2 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ATP6V0D2 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 5:33,843,591...33,892,446
Ensembl chr 5:33,843,519...33,892,462
|
|
G |
Atp6v1e2 |
ATPase H+ transporting V1 subunit E2 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ATP6V1E2 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 6:10,510,370...10,517,059
Ensembl chr 6:10,511,452...10,515,370
|
|
G |
Atp6v1g3 |
ATPase H+ transporting V1 subunit G3 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ATP6V1G3 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr13:55,265,794...55,288,651
Ensembl chr13:55,274,199...55,288,651
|
|
G |
Atp7a |
ATPase copper transporting alpha |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ATP7A mRNA |
CTD |
PMID:29950665 |
|
NCBI chr X:77,076,085...77,193,644
Ensembl chr X:77,076,106...77,193,644
|
|
G |
Atp8b1 |
ATPase phospholipid transporting 8B1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ATP8B1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr18:60,013,388...60,152,920
Ensembl chr18:60,013,382...60,095,354
|
|
G |
Atp8b2 |
ATPase phospholipid transporting 8B2 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ATP8B2 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 2:189,285,961...189,306,947
Ensembl chr 2:189,285,953...189,307,108
|
|
G |
Avpr1a |
arginine vasopressin receptor 1A |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of AVPR1A mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 7:67,341,366...67,345,290
Ensembl chr 7:67,341,080...67,345,308
|
|
G |
Avpr1b |
arginine vasopressin receptor 1B |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of AVPR1B mRNA |
CTD |
PMID:29950665 |
|
NCBI chr13:48,367,307...48,378,831
Ensembl chr13:48,367,307...48,378,831
|
|
G |
Avpr2 |
arginine vasopressin receptor 2 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of AVPR2 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr X:156,889,006...156,892,707
Ensembl chr X:156,889,410...156,891,213
|
|
G |
Axin2 |
axin 2 |
multiple interactions |
ISO |
[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of AXIN2 mRNA; [Dextran Sulfate co-treated with Azoxymethane] results in increased expression of AXIN2 protein; pristimerin inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of AXIN2 mRNA]; pristimerin inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of AXIN2 protein] |
CTD |
PMID:31715269 |
|
NCBI chr10:97,212,483...97,238,824
Ensembl chr10:97,212,432...97,239,642
|
|
G |
B3gnt3 |
UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 3 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of B3GNT3 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr16:20,123,948...20,133,482
Ensembl chr16:20,123,948...20,133,322
|
|
G |
B3gnt7 |
UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 7 |
decreases expression multiple interactions |
ISO |
Dextran Sulfate results in decreased expression of B3GNT7 protein Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of B3GNT7 protein] |
CTD |
PMID:32272095 |
|
NCBI chr 9:93,326,283...93,330,234
Ensembl chr 9:93,326,283...93,330,233
|
|
G |
B3gnt8 |
UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 8 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of B3GNT8 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 1:82,419,264...82,422,852
Ensembl chr 1:82,419,947...82,422,846
|
|
G |
Baat |
bile acid CoA:amino acid N-acyltransferase |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of BAAT mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 5:64,768,397...64,777,368
Ensembl chr 5:64,768,401...64,777,368
|
|
G |
Banf1 |
BAF nuclear assembly factor 1 |
multiple interactions decreases expression |
ISO |
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of BANF1 protein] |
CTD |
PMID:32272095 |
|
NCBI chr 1:220,744,195...220,746,224
Ensembl chr 1:220,744,195...220,746,224
|
|
G |
Bank1 |
B-cell scaffold protein with ankyrin repeats 1 |
increases expression |
ISO |
Dextran Sulfate results in increased expression of BANK1 mRNA |
CTD |
PMID:23894361 |
|
NCBI chr 2:241,273,763...241,545,527
Ensembl chr 2:241,273,763...241,545,250
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions |
ISO |
[RASSF1 gene mutant form results in increased susceptibility to Dextran Sulfate] which results in increased expression of BAX mRNA; [RASSF1 gene mutant form results in increased susceptibility to Dextran Sulfate] which results in increased expression of BAX protein |
CTD |
PMID:24146755 |
|
NCBI chr 1:101,451,801...101,457,207
Ensembl chr 1:101,451,802...101,457,207
|
|
G |
Bche |
butyrylcholinesterase |
multiple interactions decreases activity |
ISO |
[Chlorpyrifos co-treated with Dextran Sulfate] results in decreased activity of BCHE protein Dextran Sulfate results in decreased activity of BCHE protein |
CTD |
PMID:31226429 PMID:31807802 |
|
NCBI chr 2:171,104,476...171,196,186
Ensembl chr 2:171,100,140...171,196,395
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions |
ISO |
[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of BCL2 protein; Aspirin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of BCL2 protein]; Camptothecin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of BCL2 protein]; Plant Extracts inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of BCL2 protein] |
CTD |
PMID:25449198 |
|
NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
|
|
G |
Bdkrb1 |
bradykinin receptor B1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of BDKRB1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 6:129,437,423...129,441,553
Ensembl chr 6:129,438,158...129,440,574
|
|
G |
Bdkrb2 |
bradykinin receptor B2 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of BDKRB2 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 6:129,399,468...129,429,676
Ensembl chr 6:129,399,468...129,429,676
|
|
G |
Becn1 |
beclin 1 |
multiple interactions increases expression |
ISO |
2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[Dextran Sulfate co-treated with alpinetin] results in increased expression of BECN1 protein]; [Dextran Sulfate co-treated with 6-formylindolo(3,2-b)carbazole] results in increased expression of BECN1 protein; [Dextran Sulfate co-treated with alpinetin] results in increased expression of BECN1 protein; [Dextran Sulfate co-treated with Lipopolysaccharides] results in increased expression of BECN1 protein; [HU 308 co-treated with Dextran Sulfate] affects the expression of BECN1 protein; CNR2 protein affects the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased expression of BECN1 protein]; HU 308 promotes the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased expression of BECN1 protein]; Leucine inhibits the reaction [[Dextran Sulfate co-treated with alpinetin] results in increased expression of BECN1 protein]; Nicotine promotes the reaction [Dextran Sulfate results in increased expression of BECN1 protein] dorsomorphin inhibits the reaction [Nicotine promotes the reaction [Dextran Sulfate results in increased expression of BECN1 protein]]; Nicotine promotes the reaction [Dextran Sulfate results in increased expression of BECN1 protein] |
CTD |
PMID:27611972 PMID:31676321 PMID:31926917 |
|
NCBI chr10:89,209,944...89,225,297
Ensembl chr10:89,209,940...89,225,297
|
|
G |
Best1 |
bestrophin 1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of BEST1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 1:226,033,146...226,049,893
Ensembl chr 1:226,030,875...226,049,929
|
|
G |
Bgn |
biglycan |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of BGN mRNA |
CTD |
PMID:29950665 |
|
NCBI chr X:157,319,042...157,331,204
Ensembl chr X:157,319,046...157,331,204
|
|
G |
Birc5 |
baculoviral IAP repeat-containing 5 |
multiple interactions |
ISO |
[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of BIRC5 protein; Aspirin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of BIRC5 protein]; Camptothecin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of BIRC5 protein]; Plant Extracts inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of BIRC5 protein] |
CTD |
PMID:25449198 |
|
NCBI chr10:106,856,097...106,864,419
Ensembl chr10:106,856,097...106,864,413
|
|
G |
Bmp1 |
bone morphogenetic protein 1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of BMP1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr15:52,166,401...52,210,786
Ensembl chr15:52,166,401...52,210,746
|
|
G |
Bmp10 |
bone morphogenetic protein 10 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of BMP10 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 4:119,224,906...119,230,534
Ensembl chr 4:119,225,040...119,230,728
|
|
G |
Bmp7 |
bone morphogenetic protein 7 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of BMP7 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 3:170,879,972...170,955,820
Ensembl chr 3:170,879,973...170,955,399
|
|
G |
Bmpr1b |
bone morphogenetic protein receptor type 1B |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of BMPR1B mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 2:247,392,195...247,662,026
Ensembl chr 2:247,403,920...247,446,882
|
|
G |
Bmpr2 |
bone morphogenetic protein receptor type 2 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of BMPR2 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 9:66,568,074...66,683,019
Ensembl chr 9:66,568,074...66,676,494
|
|
G |
Bst1 |
bone marrow stromal cell antigen 1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of BST1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr14:71,798,218...71,814,540
Ensembl chr14:71,798,651...71,814,523
|
|
G |
Btf3l4 |
basic transcription factor 3-like 4 |
decreases expression multiple interactions |
ISO |
Dextran Sulfate results in decreased expression of BTF3L4 protein Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of BTF3L4 protein] |
CTD |
PMID:32272095 |
|
NCBI chr 5:128,432,049...128,450,530
Ensembl chr 5:128,432,433...128,446,725
|
|
G |
C1galt1 |
core 1 synthase, glycoprotein-N-acetylgalactosamine 3-beta-galactosyltransferase, 1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of C1GALT1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 4:33,890,353...33,943,219
Ensembl chr 4:33,890,349...33,943,211
|
|
G |
C1galt1c1 |
C1GALT1-specific chaperone 1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of C1GALT1C1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr X:124,921,686...124,926,171
Ensembl chr X:124,921,728...124,926,171
|
|
G |
C1qa |
complement C1q A chain |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of C1QA mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 5:155,261,254...155,264,101
Ensembl chr 5:155,261,250...155,264,143
|
|
G |
C1qb |
complement C1q B chain |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of C1QB mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 5:155,246,444...155,251,995
Ensembl chr 5:155,246,447...155,252,003
|
|
G |
C1s |
complement C1s |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of C1S2 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 4:157,143,592...157,155,592
Ensembl chr 4:157,143,592...157,155,609
|
|
G |
C3 |
complement C3 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of C3 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 9:9,721,137...9,747,084
Ensembl chr 9:9,721,105...9,747,167
|
|
G |
C3ar1 |
complement C3a receptor 1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of C3AR1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 4:155,681,767...155,691,240
Ensembl chr 4:155,684,029...155,690,869
|
|
G |
C4b |
complement C4B (Chido blood group) |
multiple interactions increases expression |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of C4B mRNA; Erianin inhibits the reaction [Dextran Sulfate results in increased expression of C4B protein] |
CTD |
PMID:29950665 PMID:32272095 |
|
NCBI chr20:4,302,344...4,316,752
Ensembl chr20:4,302,344...4,316,715
|
|
G |
C5ar1 |
complement C5a receptor 1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of C5AR1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 1:78,186,777...78,195,132
Ensembl chr 1:78,186,776...78,195,328
|
|
G |
Ca3 |
carbonic anhydrase 3 |
multiple interactions increases expression |
ISO |
Erianin inhibits the reaction [Dextran Sulfate results in increased expression of CA3 protein] |
CTD |
PMID:32272095 |
|
NCBI chr 2:88,126,519...88,136,063
Ensembl chr 2:88,126,667...88,135,410
|
|
G |
Ca4 |
carbonic anhydrase 4 |
multiple interactions decreases expression |
ISO |
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of CA4 protein] |
CTD |
PMID:32272095 |
|
NCBI chr10:72,272,286...72,281,069
Ensembl chr10:72,272,248...72,281,067
|
|
G |
Cab39 |
calcium binding protein 39 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CAB39 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 9:92,834,327...92,895,778
Ensembl chr 9:92,834,357...92,895,778
|
|
G |
Cacna1f |
calcium voltage-gated channel subunit alpha1 F |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CACNA1F mRNA |
CTD |
PMID:29950665 |
|
NCBI chr X:15,712,709...15,741,135
Ensembl chr X:15,712,713...15,741,103
|
|
G |
Cacna1s |
calcium voltage-gated channel subunit alpha1 S |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CACNA1S mRNA |
CTD |
PMID:29950665 |
|
NCBI chr13:52,889,570...52,964,558
Ensembl chr13:52,889,737...52,964,155
|
|
G |
Calca |
calcitonin-related polypeptide alpha |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CALCA mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 1:184,184,018...184,188,922
Ensembl chr 1:184,184,020...184,188,911
|
|
G |
Calcb |
calcitonin-related polypeptide, beta |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CALCB mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 1:184,271,116...184,276,480
Ensembl chr 1:184,271,590...184,276,475
|
|
G |
Calm1 |
calmodulin 1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CALM1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 6:124,217,241...124,225,292
Ensembl chr 6:124,217,241...124,225,292
|
|
G |
Camk2g |
calcium/calmodulin-dependent protein kinase II gamma |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CAMK2G mRNA |
CTD |
PMID:29950665 |
|
NCBI chr15:3,936,721...3,995,740
Ensembl chr15:3,936,786...3,995,915
|
|
G |
Camk4 |
calcium/calmodulin-dependent protein kinase IV |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CAMK4 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr18:25,746,878...25,975,962
Ensembl chr18:25,749,098...25,965,957
|
|
G |
Camkk1 |
calcium/calmodulin-dependent protein kinase kinase 1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CAMKK1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr10:59,585,023...59,608,180
Ensembl chr10:59,585,072...59,608,165
|
|
G |
Capn13 |
calpain 13 |
multiple interactions decreases expression |
ISO |
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of CAPN13 protein] |
CTD |
PMID:32272095 |
|
NCBI chr 6:24,579,590...24,676,536
Ensembl chr 6:24,579,622...24,676,524
|
|
G |
Car2 |
carbonic anhydrase 2 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CAR2 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 2:88,097,740...88,112,868
Ensembl chr 2:88,097,720...88,113,029
|
|
G |
Casp1 |
caspase 1 |
multiple interactions increases expression |
ISO EXP |
3-methyladenine affects the reaction [[HU 308 co-treated with Dextran Sulfate] affects the cleavage of CASP1 protein]; [Dextran Sulfate co-treated with Lipopolysaccharides] results in increased cleavage of CASP1 protein; [Dextran Sulfate co-treated with Zearalenone] results in increased expression of CASP1 mRNA; [Dextran Sulfate co-treated with Zearalenone] results in increased expression of CASP1 protein; [HU 308 co-treated with Dextran Sulfate] affects the cleavage of CASP1 protein; ATG5 protein affects the reaction [HU 308 inhibits the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased cleavage of CASP1 protein]]; CNR2 protein affects the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased cleavage of CASP1 protein]; dorsomorphin inhibits the reaction [HU 308 inhibits the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased cleavage of CASP1 protein]]; HU 308 inhibits the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased cleavage of CASP1 protein] MCC-950 inhibits the reaction [Dextran Sulfate results in increased expression of CASP1 protein]; MCC-950 promotes the reaction [tripterine inhibits the reaction [Dextran Sulfate results in increased expression of CASP1 protein]]; tripterine inhibits the reaction [Dextran Sulfate results in increased expression of CASP1 protein] Dextran Sulfate results in increased expression of CASP1 mRNA; Dextran Sulfate results in increased expression of CASP1 protein |
CTD |
PMID:27611972 PMID:30270565 PMID:32470352 |
|
NCBI chr 8:2,605,743...2,614,637
Ensembl chr 8:2,604,962...2,614,631
|
|
G |
Casp3 |
caspase 3 |
increases cleavage increases activity multiple interactions |
ISO |
Dextran Sulfate results in increased cleavage of CASP3 protein Dextran Sulfate results in increased activity of CASP3 protein 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [alpinetin inhibits the reaction [Dextran Sulfate results in increased cleavage of CASP3 protein]]; 6-formylindolo(3,2-b)carbazole inhibits the reaction [Dextran Sulfate results in increased cleavage of CASP3 protein]; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CASP3 mRNA; alpinetin inhibits the reaction [Dextran Sulfate results in increased cleavage of CASP3 protein]; EIF2AK2 protein affects the reaction [Dextran Sulfate results in increased activity of CASP3 protein]; Leucine inhibits the reaction [alpinetin inhibits the reaction [Dextran Sulfate results in increased cleavage of CASP3 protein]]; Plant Extracts inhibits the reaction [Dextran Sulfate results in increased cleavage of CASP3 protein] |
CTD |
PMID:21989142 PMID:27920257 PMID:29950665 PMID:31676321 |
|
NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
|
|
G |
Casp8 |
caspase 8 |
multiple interactions decreases expression |
ISO |
15,16-dihydrotanshinone I inhibits the reaction [Dextran Sulfate results in decreased expression of CASP8 protein] |
CTD |
PMID:29496522 |
|
NCBI chr 9:65,614,142...65,662,624
Ensembl chr 9:65,614,142...65,662,106
|
|
G |
Cat |
catalase |
decreases activity multiple interactions |
ISO |
Dextran Sulfate results in decreased activity of CAT protein mangiferin inhibits the reaction [Dextran Sulfate results in decreased activity of CAT protein] |
CTD |
PMID:27125760 |
|
NCBI chr 3:93,379,872...93,412,058
Ensembl chr 3:93,379,874...93,412,058
|
|
G |
Cbr3 |
carbonyl reductase 3 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CBR3 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr11:33,909,417...33,917,674
Ensembl chr11:33,909,439...33,917,674
|
|
G |
Ccdc158 |
coiled-coil domain containing 158 |
decreases expression multiple interactions |
ISO |
Dextran Sulfate results in decreased expression of CCDC158 protein Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of CCDC158 protein] |
CTD |
PMID:32272095 |
|
NCBI chr14:16,917,138...16,976,240
Ensembl chr14:16,924,960...16,974,514
|
|
G |
Cckbr |
cholecystokinin B receptor |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CCKBR mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 1:170,262,218...170,272,298
Ensembl chr 1:170,262,156...170,272,298
|
|
G |
Ccl11 |
C-C motif chemokine ligand 11 |
increases secretion multiple interactions |
ISO |
Dextran Sulfate results in increased secretion of CCL11 protein [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CCL11 mRNA; Tetrachlorodibenzodioxin inhibits the reaction [Dextran Sulfate results in increased secretion of CCL11 protein] |
CTD |
PMID:21858153 PMID:29950665 |
|
NCBI chr10:69,434,965...69,439,566
Ensembl chr10:69,434,941...69,439,575
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions increases expression increases secretion |
ISO |
[RASSF1 gene mutant form results in increased susceptibility to Dextran Sulfate] which results in increased secretion of CCL2 protein; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CCL2 mRNA; Tetrachlorodibenzodioxin inhibits the reaction [Dextran Sulfate results in increased secretion of CCL2 protein] Dextran Sulfate results in increased expression of CCL2 mRNA |
CTD |
PMID:19645018 PMID:20079348 PMID:21858153 PMID:24146755 PMID:29950665 PMID:31807802 |
|
NCBI chr10:69,412,065...69,413,863
Ensembl chr10:69,412,017...69,413,870
|
|
G |
Ccl21 |
C-C motif chemokine ligand 21 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CCL21A mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 5:58,197,678...58,198,782
Ensembl chr 5:58,197,680...58,198,782
|
|
G |
Ccl24 |
C-C motif chemokine ligand 24 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CCL24 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr12:24,131,529...24,152,626
Ensembl chr12:24,148,567...24,152,625
|
|
G |
Ccl25 |
C-C motif chemokine ligand 25 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CCL25 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr12:2,429,492...2,438,928
Ensembl chr12:2,429,509...2,438,817
|
|
G |
Ccl28 |
C-C motif chemokine ligand 28 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CCL28 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 2:52,379,341...52,403,979
Ensembl chr 2:52,379,341...52,404,246
|
|
G |
Ccl3 |
C-C motif chemokine ligand 3 |
increases expression multiple interactions |
ISO EXP |
Dextran Sulfate results in increased expression of CCL3 mRNA Dextran Sulfate results in increased expression of CCL3 protein Hesperidin inhibits the reaction [Dextran Sulfate results in increased expression of CCL3 protein] |
CTD |
PMID:19645018 PMID:30811821 |
|
NCBI chr10:70,869,516...70,871,066
Ensembl chr10:70,869,513...70,871,066
|
|
G |
Ccl4 |
C-C motif chemokine ligand 4 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CCL4 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr10:70,870,926...70,886,357
Ensembl chr10:70,884,531...70,886,355
|
|
G |
Ccl6 |
C-C motif chemokine ligand 6 |
decreases expression |
ISO |
Dextran Sulfate results in decreased expression of CCL6 mRNA |
CTD |
PMID:19645018 |
|
NCBI chr10:70,798,118...70,802,750
Ensembl chr10:70,797,124...70,802,782
|
|
G |
Ccl7 |
C-C motif chemokine ligand 7 |
increases expression multiple interactions |
ISO |
Dextran Sulfate results in increased expression of CCL7 mRNA [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CCL7 mRNA |
CTD |
PMID:19645018 PMID:29950665 |
|
NCBI chr10:69,423,083...69,424,933
Ensembl chr10:69,423,086...69,424,979
|
|
G |
Ccnd1 |
cyclin D1 |
multiple interactions |
ISO |
[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of CCND1 mRNA; [Dextran Sulfate co-treated with Azoxymethane] results in increased expression of CCND1 protein; pristimerin inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of CCND1 mRNA]; pristimerin inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of CCND1 protein] |
CTD |
PMID:31715269 |
|
NCBI chr 1:218,090,750...218,100,447
Ensembl chr 1:218,090,750...218,100,325
|
|
G |
Ccr2 |
C-C motif chemokine receptor 2 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CCR2 mRNA |
CTD |
PMID:29950665 |
|
|
|
G |
Ccr4 |
C-C motif chemokine receptor 4 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CCR4 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 8:122,530,152...122,535,959
Ensembl chr 8:122,530,624...122,532,070
|
|
G |
Ccr5 |
C-C motif chemokine receptor 5 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CCR5 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 8:133,192,398...133,215,599
Ensembl chr 8:133,197,032...133,215,614
|
|
G |
Ccr8 |
C-C motif chemokine receptor 8 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CCR8 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 8:128,779,552...128,782,531
Ensembl chr 8:128,781,395...128,782,456
|
|
G |
Ccrl2 |
C-C motif chemokine receptor like 2 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CCRL2 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 8:119,324,298...119,326,954
Ensembl chr 8:119,324,613...119,326,938
|
|
G |
Cd14 |
CD14 molecule |
affects response to substance multiple interactions |
ISO |
Dextran Sulfate affects the susceptibility to CD14 protein [Dextran Sulfate affects the susceptibility to CD14 protein] which affects the expression of IFNG mRNA; CD14 protein inhibits the reaction [Dextran Sulfate results in increased expression of TNF mRNA] |
CTD |
PMID:28411859 |
|
NCBI chr18:29,560,341...29,562,290
Ensembl chr18:29,560,365...29,562,153
|
|
G |
Cd177 |
CD177 molecule |
increases expression |
ISO |
Dextran Sulfate results in increased expression of CD177 mRNA |
CTD |
PMID:23894361 |
|
NCBI chr 1:82,964,683...82,987,306
Ensembl chr 1:82,964,683...82,987,253
|
|
G |
Cd180 |
CD180 molecule |
increases expression multiple interactions |
ISO |
Dextran Sulfate results in increased expression of CD180 mRNA [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CD180 mRNA |
CTD |
PMID:23894361 PMID:29950665 |
|
NCBI chr 2:32,820,275...32,833,223
Ensembl chr 2:32,820,322...32,833,125
|
|
G |
Cd19 |
CD19 molecule |
increases expression |
ISO |
Dextran Sulfate results in increased expression of CD19 mRNA |
CTD |
PMID:23894361 |
|
NCBI chr 1:197,815,422...197,822,123
Ensembl chr 1:197,815,413...197,821,936
|
|
G |
Cd200 |
Cd200 molecule |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CD200 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr11:60,371,617...60,398,450
Ensembl chr11:60,371,684...60,403,196
|
|
G |
Cd247 |
Cd247 molecule |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CD247 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr13:83,996,045...84,071,408
Ensembl chr13:83,996,080...84,071,400
|
|
G |
Cd274 |
CD274 molecule |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CD274 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 1:247,519,890...247,539,659
Ensembl chr 1:247,519,939...247,537,943
|
|
G |
Cd28 |
Cd28 molecule |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CD28 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 9:67,546,408...67,573,858
Ensembl chr 9:67,546,408...67,571,871
|
|
G |
Cd4 |
Cd4 molecule |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CD4 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 4:157,381,862...157,408,357
Ensembl chr 4:157,383,052...157,408,176
|
|
G |
Cd44 |
CD44 molecule (Indian blood group) |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with Dextran Sulfate] results in increased expression of CD44 mRNA |
CTD |
PMID:26271895 |
|
NCBI chr 3:92,695,083...92,783,820
Ensembl chr 3:92,696,313...92,783,658
|
|
G |
Cd52 |
CD52 molecule |
increases expression |
ISO |
Dextran Sulfate results in increased expression of CD52 mRNA |
CTD |
PMID:23894361 |
|
NCBI chr 5:152,322,910...152,324,469
Ensembl chr 5:152,322,916...152,324,469
|
|
G |
Cd53 |
Cd53 molecule |
increases expression |
ISO |
Dextran Sulfate results in increased expression of CD53 mRNA |
CTD |
PMID:23894361 |
|
NCBI chr 2:209,489,279...209,537,098
Ensembl chr 2:209,489,279...209,537,087
|
|
G |
Cd55 |
CD55 molecule (Cromer blood group) |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CD55 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr13:47,125,156...47,153,557
Ensembl chr13:47,126,741...47,154,292
|
|
G |
Cd72 |
Cd72 molecule |
increases expression |
ISO |
Dextran Sulfate results in increased expression of CD72 mRNA |
CTD |
PMID:23894361 |
|
NCBI chr 5:58,943,021...58,950,373
Ensembl chr 5:58,943,027...58,950,373
|
|
G |
Cd74 |
CD74 molecule |
increases expression |
ISO |
Dextran Sulfate results in increased expression of CD74 mRNA |
CTD |
PMID:23894361 |
|
NCBI chr18:56,071,420...56,080,851
Ensembl chr18:56,071,478...56,080,849
|
|
G |
Cd79a |
CD79a molecule |
increases expression |
ISO |
Dextran Sulfate results in increased expression of CD79A mRNA |
CTD |
PMID:23894361 |
|
NCBI chr 1:81,763,609...81,768,039
Ensembl chr 1:81,763,614...81,767,980
|
|
G |
Cd79b |
CD79b molecule |
increases expression |
ISO |
Dextran Sulfate results in increased expression of CD79B mRNA |
CTD |
PMID:23894361 |
|
NCBI chr10:94,497,445...94,500,591
Ensembl chr10:94,497,448...94,500,591
|
|
G |
Cd86 |
CD86 molecule |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CD86 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr11:67,060,305...67,117,990
Ensembl chr11:67,082,193...67,118,795
|
|
G |
Cda |
cytidine deaminase |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CDA mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 5:156,703,579...156,734,541
Ensembl chr 5:156,703,579...156,734,541
|
|
G |
Cdh1 |
cadherin 1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CDH1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr19:38,768,467...38,838,395
Ensembl chr19:38,768,467...38,838,395
|
|
G |
Cdh5 |
cadherin 5 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CDH5 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr19:1,025,122...1,074,333
Ensembl chr19:1,023,683...1,074,365
|
|
G |
Cdhr2 |
cadherin-related family member 2 |
decreases expression multiple interactions |
ISO |
Dextran Sulfate results in decreased expression of CDHR2 protein Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of CDHR2 protein] |
CTD |
PMID:32272095 |
|
NCBI chr17:10,415,044...10,450,589
Ensembl chr17:10,415,123...10,439,691
|
|
G |
Cdkn1c |
cyclin-dependent kinase inhibitor 1C |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CDKN1C mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 1:216,661,067...216,663,791
Ensembl chr 1:216,661,080...216,663,721
|
|
G |
Cdx2 |
caudal type homeo box 2 |
increases expression multiple interactions |
ISO |
Dextran Sulfate results in increased expression of CDX2 protein 6-formylindolo(3,2-b)carbazole inhibits the reaction [Dextran Sulfate results in increased expression of CDX2 protein] |
CTD |
PMID:29680209 |
|
NCBI chr12:9,464,026...9,470,565
Ensembl chr12:9,464,026...9,470,565
|
|
G |
Cel |
carboxyl ester lipase |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CEL mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 3:7,134,021...7,141,522
Ensembl chr 3:7,134,021...7,141,522
|
|
G |
Ces1d |
carboxylesterase 1D |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CES1D mRNA |
CTD |
PMID:29950665 |
|
NCBI chr19:15,195,514...15,239,827
Ensembl chr19:15,033,108...15,239,821
|
|
G |
Ces2c |
carboxylesterase 2C |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CES2C mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 1:282,640,752...282,648,319
Ensembl chr 1:282,638,017...282,702,424
|
|
G |
Cfh |
complement factor H |
multiple interactions increases expression |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CFH mRNA; Erianin inhibits the reaction [Dextran Sulfate results in increased expression of CFH protein] |
CTD |
PMID:29950665 PMID:32272095 |
|
NCBI chr13:56,979,155...57,080,540
Ensembl chr13:56,978,607...57,080,622
|
|
G |
Cflar |
CASP8 and FADD-like apoptosis regulator |
multiple interactions |
ISO |
[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CFLAR protein; Aspirin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CFLAR protein]; Camptothecin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CFLAR protein]; Plant Extracts inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CFLAR protein] |
CTD |
PMID:25449198 |
|
NCBI chr 9:65,534,608...65,586,395
Ensembl chr 9:65,534,704...65,587,251
|
|
G |
Cftr |
CF transmembrane conductance regulator |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CFTR mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 4:42,693,263...42,860,679
Ensembl chr 4:42,692,836...42,860,676
|
|
G |
Cherp |
calcium homeostasis endoplasmic reticulum protein |
multiple interactions decreases expression |
ISO |
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of CHERP protein] |
CTD |
PMID:32272095 |
|
NCBI chr16:19,068,783...19,081,837
Ensembl chr16:19,068,783...19,081,837
|
|
G |
Chmp2a |
charged multivesicular body protein 2A |
decreases expression multiple interactions |
ISO |
Dextran Sulfate results in decreased expression of CHMP2A protein Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of CHMP2A protein] |
CTD |
PMID:32272095 |
|
NCBI chr 1:65,540,808...65,543,708
Ensembl chr 1:65,541,322...65,543,707
|
|
G |
Chn2 |
chimerin 2 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CHN2 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 4:84,423,708...84,452,989
Ensembl chr 4:84,194,347...84,454,500
|
|
G |
Chrdl2 |
chordin-like 2 |
increases expression |
ISO |
Dextran Sulfate results in increased expression of CHRDL2 mRNA |
CTD |
PMID:23894361 |
|
NCBI chr 1:165,008,997...165,036,431
Ensembl chr 1:165,008,912...165,036,435
|
|
G |
Chrm4 |
cholinergic receptor, muscarinic 4 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CHRM4 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 3:80,833,272...80,841,165
Ensembl chr 3:80,833,272...80,841,006
|
|
G |
Chrna2 |
cholinergic receptor nicotinic alpha 2 subunit |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CHRNA2 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr15:42,808,897...42,825,179
Ensembl chr15:42,808,897...42,825,179
|
|
G |
Chrna7 |
cholinergic receptor nicotinic alpha 7 subunit |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CHRNA7 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 1:123,897,341...124,039,263
Ensembl chr 1:123,899,657...124,039,196
|
|
G |
Chrnb3 |
cholinergic receptor nicotinic beta 3 subunit |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CHRNB3 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr16:68,876,442...68,913,628
Ensembl chr16:68,875,709...68,913,628
|
|
G |
Chrne |
cholinergic receptor nicotinic epsilon subunit |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CHRNE mRNA |
CTD |
PMID:29950665 |
|
NCBI chr10:57,238,960...57,246,750
Ensembl chr10:57,238,946...57,243,435
|
|
G |
Chst11 |
carbohydrate sulfotransferase 11 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CHST11 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 7:26,641,856...26,890,503
Ensembl chr 7:26,645,422...26,859,716
|
|
G |
Chuk |
component of inhibitor of nuclear factor kappa B kinase complex |
increases expression multiple interactions |
ISO |
Dextran Sulfate results in increased expression of CHUK protein modified form notoginsenoside R1 inhibits the reaction [Dextran Sulfate results in increased expression of CHUK protein modified form] |
CTD |
PMID:25472953 |
|
NCBI chr 1:263,848,829...263,884,354
Ensembl chr 1:263,848,884...263,885,169
|
|
G |
Clca1 |
chloride channel accessory 1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CLCA1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 2:250,897,980...250,923,711
Ensembl chr 2:250,897,969...250,923,744
|
|
G |
Clca4 |
chloride channel accessory 4 |
increases expression |
ISO |
Dextran Sulfate results in increased expression of CLCA4 mRNA |
CTD |
PMID:23894361 |
|
NCBI chr 2:250,842,939...250,864,060
Ensembl chr 2:250,843,165...250,862,419
|
|
G |
Clcn2 |
chloride voltage-gated channel 2 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CLCN2 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr11:82,862,664...82,876,165
Ensembl chr11:83,883,879...83,897,394
|
|
G |
Clcn3 |
chloride voltage-gated channel 3 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CLCN3 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr16:32,448,821...32,520,649
Ensembl chr16:32,449,116...32,519,148
|
|
G |
Cldn1 |
claudin 1 |
multiple interactions decreases expression |
ISO |
[SB 203580 co-treated with Dextran Sulfate] results in decreased expression of CLDN1 protein; [Win 55212-2 co-treated with Dextran Sulfate] results in decreased expression of CLDN1 protein Dextran Sulfate results in decreased expression of CLDN1 protein |
CTD |
PMID:27920472 |
|
NCBI chr11:77,815,216...77,830,373
Ensembl chr11:77,815,181...77,830,416
|
|
G |
Cldn11 |
claudin 11 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CLDN11 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 2:115,823,541...115,836,846
Ensembl chr 2:115,823,538...115,836,846
|
|
G |
Cldn2 |
claudin 2 |
multiple interactions increases expression |
ISO |
6-formylindolo(3,2-b)carbazole inhibits the reaction [Dextran Sulfate results in increased expression of CLDN2 mRNA]; 6-formylindolo(3,2-b)carbazole inhibits the reaction [Dextran Sulfate results in increased expression of CLDN2 protein]; [Benzo(a)pyrene co-treated with Dextran Sulfate] results in decreased expression of CLDN2 mRNA Dextran Sulfate results in increased expression of CLDN2 mRNA; Dextran Sulfate results in increased expression of CLDN2 protein |
CTD |
PMID:26271895 PMID:29680209 |
|
NCBI chr X:111,122,552...111,133,188
Ensembl chr X:111,122,552...111,137,769
|
|
G |
Cma1 |
chymase 1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CMA1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr15:34,601,037...34,603,819
Ensembl chr15:34,601,037...34,603,819
|
|
G |
Cmas |
cytidine monophosphate N-acetylneuraminic acid synthetase |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CMAS mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 4:176,994,129...177,012,445
Ensembl chr 4:176,994,129...177,012,444
|
|
G |
Cnga4 |
cyclic nucleotide gated channel subunit alpha 4 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CNGA4 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 1:170,238,959...170,246,858
Ensembl chr 1:170,242,846...170,246,858
|
|
G |
Cnr1 |
cannabinoid receptor 1 |
decreases response to substance increases expression multiple interactions |
ISO |
CNR1 results in decreased susceptibility to Dextran Sulfate Dextran Sulfate results in increased expression of CNR1 protein SB 203580 inhibits the reaction [Dextran Sulfate results in increased expression of CNR1 protein]; Serotonin inhibits the reaction [Dextran Sulfate results in increased expression of CNR1 protein] |
CTD |
PMID:15085199 PMID:27920472 PMID:30611738 |
|
NCBI chr 5:49,307,584...49,333,064
Ensembl chr 5:49,311,030...49,333,056
|
|
G |
Cnr2 |
cannabinoid receptor 2 |
multiple interactions affects response to substance increases expression |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CNR2 mRNA; CNR2 protein affects the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in decreased expression of SQSTM1 protein]; CNR2 protein affects the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased cleavage of CASP1 protein]; CNR2 protein affects the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased expression of and results in increased secretion of IL1B protein]; CNR2 protein affects the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased expression of BECN1 protein]; CNR2 protein affects the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased expression of IL1B mRNA]; CNR2 protein affects the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased expression of NLRP3 protein]; CNR2 protein affects the reaction [Dextran Sulfate results in decreased phosphorylation of MTOR protein]; CNR2 protein affects the reaction [Dextran Sulfate results in decreased phosphorylation of RPS6KB1 protein]; CNR2 protein affects the susceptibility to [Azoxymethane co-treated with Dextran Sulfate]; SB 203580 inhibits the reaction [Dextran Sulfate results in increased expression of CNR2 protein] CNR2 protein affects the susceptibility to Dextran Sulfate |
CTD |
PMID:27611972 PMID:27920472 PMID:29950665 PMID:32942172 |
|
NCBI chr 5:154,242,010...154,268,126
Ensembl chr 5:154,260,062...154,268,126
|
|
G |
Cntfr |
ciliary neurotrophic factor receptor |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CNTFR mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 5:58,041,114...58,078,687
Ensembl chr 5:58,041,146...58,078,545
|
|
G |
Cntn1 |
contactin 1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CNTN1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 7:133,290,606...133,588,314
Ensembl chr 7:133,400,485...133,586,677
|
|
G |
Cog1 |
component of oligomeric golgi complex 1 |
multiple interactions decreases expression |
ISO |
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of COG1 protein] |
CTD |
PMID:32272095 |
|
NCBI chr10:102,167,594...102,180,569
Ensembl chr10:102,167,771...102,180,569
|
|
G |
Col11a1 |
collagen type XI alpha 1 chain |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of COL11A1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 2:216,863,423...217,056,523
Ensembl chr 2:216,863,428...217,056,523
|
|
G |
Col14a1 |
collagen type XIV alpha 1 chain |
multiple interactions increases expression |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of COL14A1 mRNA; Erianin inhibits the reaction [Dextran Sulfate results in increased expression of COL14A1 protein] |
CTD |
PMID:29950665 PMID:32272095 |
|
NCBI chr 7:95,054,877...95,274,073
Ensembl chr 7:95,074,236...95,273,298
|
|
G |
Col18a1 |
collagen type XVIII alpha 1 chain |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of COL18A1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr20:12,225,202...12,332,858
Ensembl chr20:12,225,202...12,332,858
|
|
G |
Col1a1 |
collagen type I alpha 1 chain |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of COL1A1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr10:82,745,801...82,762,790
Ensembl chr10:82,745,801...82,762,789
|
|
G |
Col23a1 |
collagen type XXIII alpha 1 chain |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of COL23A1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr10:34,846,618...34,934,991
Ensembl chr10:34,903,343...34,933,539
|
|
G |
Col28a1 |
collagen type XXVIII alpha 1 chain |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of COL28A1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 4:34,048,074...34,198,558
Ensembl chr 4:34,048,533...34,194,764
|
|
G |
Col4a1 |
collagen type IV alpha 1 chain |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of COL4A1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr16:83,522,162...83,632,153
Ensembl chr16:83,522,162...83,632,153
|
|
G |
Col4a2 |
collagen type IV alpha 2 chain |
multiple interactions decreases expression |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of COL4A2 mRNA; Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of COL4A2 protein] |
CTD |
PMID:29950665 PMID:32272095 |
|
NCBI chr16:83,386,388...83,522,169
Ensembl chr16:83,387,364...83,438,561
|
|
G |
Col5a1 |
collagen type V alpha 1 chain |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of COL5A1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 3:6,430,180...6,581,010
Ensembl chr 3:6,430,201...6,578,882
|
|
G |
Col5a2 |
collagen type V alpha 2 chain |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of COL5A2 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 9:52,091,088...52,238,735
Ensembl chr 9:52,092,511...52,238,564
|
|
G |
Col6a1 |
collagen type VI alpha 1 chain |
multiple interactions decreases expression |
ISO |
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of COL6A1 protein] |
CTD |
PMID:32272095 |
|
NCBI chr20:12,657,913...12,676,370
Ensembl chr20:12,658,065...12,675,561
|
|
G |
Col6a2 |
collagen type VI alpha 2 chain |
decreases expression multiple interactions |
ISO |
Dextran Sulfate results in decreased expression of COL6A2 protein Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of COL6A2 protein] |
CTD |
PMID:32272095 |
|
NCBI chr20:12,773,472...12,801,179
Ensembl chr20:12,773,427...12,801,180
|
|
G |
Col8a1 |
collagen type VIII alpha 1 chain |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of COL8A1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr11:44,877,690...45,006,203
Ensembl chr11:44,877,859...45,007,891
|
|
G |
Cp |
ceruloplasmin |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CP mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 2:104,744,249...104,803,034
Ensembl chr 2:104,744,461...104,799,853
|
|
G |
Cpa1 |
carboxypeptidase A1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CPA1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 4:57,952,982...57,959,109
Ensembl chr 4:57,952,982...57,959,109
|
|
G |
Cpb2 |
carboxypeptidase B2 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CPB2 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr15:57,290,849...57,339,762
Ensembl chr15:57,290,849...57,339,760
|
|
G |
Cr2 |
complement C3d receptor 2 |
increases expression |
ISO |
Dextran Sulfate results in increased expression of CR2 mRNA |
CTD |
PMID:23894361 |
|
NCBI chr13:113,890,274...113,927,824
Ensembl chr13:113,890,272...113,927,877
|
|
G |
Crhr1 |
corticotropin releasing hormone receptor 1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CRHR1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr10:92,191,473...92,233,662
Ensembl chr10:92,191,718...92,232,645
|
|
G |
Crhr2 |
corticotropin releasing hormone receptor 2 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CRHR2 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 4:85,286,371...85,329,374
Ensembl chr 4:85,286,372...85,329,362
|
|
G |
Crtap |
cartilage associated protein |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CRTAP mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 8:122,382,613...122,402,209
|
|
G |
Csf1 |
colony stimulating factor 1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CSF1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 2:210,522,370...210,550,546
Ensembl chr 2:210,522,375...210,550,560
|
|
G |
Csf2 |
colony stimulating factor 2 |
increases expression multiple interactions |
ISO |
Dextran Sulfate results in increased expression of CSF2 mRNA; Dextran Sulfate results in increased expression of CSF2 protein [Ampicillin co-treated with Vancomycin co-treated with Neomycin co-treated with Metronidazole] inhibits the reaction [Dextran Sulfate results in increased expression of CSF2 protein]; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CSF2 mRNA; Polymyxin B inhibits the reaction [Dextran Sulfate results in increased expression of CSF2 protein]; Rutin inhibits the reaction [Dextran Sulfate results in increased expression of CSF2 mRNA]; TLR4 protein affects the reaction [Dextran Sulfate results in increased expression of CSF2 protein] |
CTD |
PMID:15652231 PMID:29950665 PMID:31442584 |
|
NCBI chr10:39,602,089...39,604,070
Ensembl chr10:39,602,089...39,604,070
|
|
G |
Csf2rb |
colony stimulating factor 2 receptor subunit beta |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CSF2RB2 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 7:119,554,383...119,568,248
Ensembl chr 7:119,554,354...119,568,776
|
|
G |
Csf3r |
colony stimulating factor 3 receptor |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CSF3R mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 5:144,031,353...144,051,966
Ensembl chr 5:144,031,402...144,051,600
|
|
G |
Ctnnb1 |
catenin beta 1 |
increases expression multiple interactions |
ISO |
Dextran Sulfate results in increased expression of CTNNB1 protein [2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine co-treated with Dextran Sulfate] results in increased expression of CTNNB1 protein; [2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine co-treated with Dextran Sulfate] results in increased mutagenesis of CTNNB1 gene; [Dextran Sulfate co-treated with Azoxymethane] results in increased expression of CTNNB1 protein; CTNNB1 gene mutant form results in increased susceptibility to [2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine co-treated with Dextran Sulfate]; pristimerin inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of CTNNB1 protein] |
CTD |
PMID:15459021 PMID:16049979 PMID:27664423 PMID:31715269 |
|
NCBI chr 8:129,601,511...129,628,378
Ensembl chr 8:129,617,812...129,627,372
|
|
G |
Ctps1 |
CTP synthase 1 |
decreases expression multiple interactions |
ISO |
Dextran Sulfate results in decreased expression of CTPS1 protein Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of CTPS1 protein] |
CTD |
PMID:32272095 |
|
NCBI chr 5:139,475,934...139,505,065
Ensembl chr 5:139,475,934...139,505,065
|
|
G |
Ctsd |
cathepsin D |
multiple interactions increases expression |
ISO |
Erianin inhibits the reaction [Dextran Sulfate results in increased expression of CTSD protein] |
CTD |
PMID:32272095 |
|
NCBI chr 1:215,541,570...215,553,446
Ensembl chr 1:215,541,542...215,553,451
|
|
G |
Ctsk |
cathepsin K |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CTSK mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 2:196,655,469...196,666,447
Ensembl chr 2:196,655,469...196,666,446
|
|
G |
Ctsl |
cathepsin L |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CTSL mRNA |
CTD |
PMID:29950665 |
|
NCBI chr17:1,873,105...1,879,266
Ensembl chr17:1,872,848...1,879,279
|
|
G |
Ctss |
cathepsin S |
multiple interactions decreases expression |
ISO |
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of CTSS protein] |
CTD |
PMID:32272095 |
|
NCBI chr 2:197,655,780...197,679,768
Ensembl chr 2:197,655,786...197,679,458
|
|
G |
Cubn |
cubilin |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CUBN mRNA |
CTD |
PMID:29950665 |
|
NCBI chr17:80,584,921...80,807,181
Ensembl chr17:80,584,878...80,807,243
|
|
G |
Cx3cr1 |
C-X3-C motif chemokine receptor 1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CX3CR1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 8:128,740,756...128,754,514
Ensembl chr 8:128,740,756...128,754,514
|
|
G |
Cxadr |
CXADR, Ig-like cell adhesion molecule |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CXADR mRNA |
CTD |
PMID:29950665 |
|
NCBI chr11:16,826,269...16,873,564
Ensembl chr11:16,826,399...16,873,562
|
|
G |
Cxcl10 |
C-X-C motif chemokine ligand 10 |
multiple interactions |
ISO |
[Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CXCL10 mRNA; isoliquiritigenin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CXCL10 mRNA] |
CTD |
PMID:25026504 |
|
NCBI chr14:17,210,733...17,212,930
Ensembl chr14:17,210,733...17,212,930
|
|
G |
Cxcl13 |
C-X-C motif chemokine ligand 13 |
increases expression |
ISO |
Dextran Sulfate results in increased expression of CXCL13 mRNA |
CTD |
PMID:23894361 |
|
NCBI chr14:15,253,146...15,258,221
Ensembl chr14:15,253,125...15,258,207
|
|
G |
Cxcl14 |
C-X-C motif chemokine ligand 14 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CXCL14 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr17:9,109,731...9,117,754
Ensembl chr17:9,109,731...9,117,750
|
|
G |
Cxcl2 |
C-X-C motif chemokine ligand 2 |
multiple interactions increases expression |
ISO |
17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Dextran Sulfate results in increased expression of CXCL2 protein]; resolvin D1 inhibits the reaction [Dextran Sulfate results in increased expression of CXCL2 protein]; resolvin D2 inhibits the reaction [Dextran Sulfate results in increased expression of CXCL2 protein] |
CTD |
PMID:21724996 |
|
NCBI chr14:18,731,346...18,733,391
Ensembl chr14:18,731,378...18,733,391
|
|
G |
Cxcl3 |
C-X-C motif chemokine ligand 3 |
multiple interactions increases secretion increases expression |
ISO |
17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Dextran Sulfate results in increased expression of CXCL1 protein]; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CXCL1 mRNA; resolvin D1 inhibits the reaction [Dextran Sulfate results in increased expression of CXCL1 protein]; resolvin D2 inhibits the reaction [Dextran Sulfate results in increased expression of CXCL1 protein]; Tetrachlorodibenzodioxin inhibits the reaction [Dextran Sulfate results in increased secretion of CXCL1 protein] Dextran Sulfate results in increased expression of CXCL1 mRNA; Dextran Sulfate results in increased expression of CXCL1 protein |
CTD |
PMID:19645018 PMID:20079348 PMID:21724996 PMID:21858153 PMID:29950665 PMID:31807802 |
|
NCBI chr14:18,820,168...18,839,659
Ensembl chr14:18,820,168...18,839,595
|
|
G |
Cxcl6 |
C-X-C motif chemokine ligand 6 |
increases expression multiple interactions |
ISO |
Dextran Sulfate results in increased expression of CXCL5 mRNA [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CXCL5 mRNA |
CTD |
PMID:19645018 PMID:29950665 |
|
NCBI chr14:18,860,201...18,920,839
Ensembl chr14:18,860,264...18,862,407
|
|
G |
Cxcl9 |
C-X-C motif chemokine ligand 9 |
increases expression |
ISO |
Dextran Sulfate results in increased expression of CXCL9 mRNA |
CTD |
PMID:23894361 |
|
NCBI chr14:17,228,832...17,233,743
Ensembl chr14:17,228,856...17,234,712
|
|
G |
Cxcr2 |
C-X-C motif chemokine receptor 2 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CXCR2 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 9:81,427,275...81,435,065
Ensembl chr 9:81,427,730...81,434,102
|
|
G |
Cyba |
cytochrome b-245 alpha chain |
increases expression |
ISO |
Dextran Sulfate results in increased expression of CYBA protein |
CTD |
PMID:20637373 |
|
NCBI chr19:55,249,634...55,257,824
Ensembl chr19:55,249,616...55,257,876
|
|
G |
Cybb |
cytochrome b-245 beta chain |
increases expression |
ISO |
Dextran Sulfate results in increased expression of CYBB mRNA; Dextran Sulfate results in increased expression of CYBB protein |
CTD |
PMID:20637373 PMID:23894361 |
|
NCBI chr X:14,578,330...14,610,049
Ensembl chr X:14,578,264...14,612,547
|
|
G |
Cyfip1 |
cytoplasmic FMR1 interacting protein 1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CYFIP1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 1:114,258,773...114,347,138
Ensembl chr 1:114,258,719...114,347,137
|
|
G |
Cyfip2 |
cytoplasmic FMR1 interacting protein 2 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CYFIP2 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr10:31,278,746...31,419,235
Ensembl chr10:31,278,746...31,419,235
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
multiple interactions decreases expression |
ISO |
6-formylindolo(3,2-b)carbazole inhibits the reaction [Dextran Sulfate results in decreased expression of CYP1A1 mRNA]; 6-formylindolo(3,2-b)carbazole inhibits the reaction [Dextran Sulfate results in decreased expression of CYP1A1 protein] Dextran Sulfate results in decreased expression of CYP1A1 mRNA; Dextran Sulfate results in decreased expression of CYP1A1 protein |
CTD |
PMID:29680209 |
|
NCBI chr 8:62,472,087...62,478,122
Ensembl chr 8:62,472,095...62,478,147
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
multiple interactions decreases activity |
EXP |
[Dextran Sulfate results in decreased activity of CYP1A2 protein] which results in decreased chemical synthesis of Acetaminophen |
CTD |
PMID:28438436 |
|
NCBI chr 8:62,451,360...62,458,244
Ensembl chr 8:62,451,329...62,458,301
|
|
G |
Cyp21a1 |
cytochrome P450, family 21, subfamily a, polypeptide 1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP21A1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr20:4,486,213...4,489,358
Ensembl chr20:4,486,219...4,489,550
|
|
G |
Cyp27b1 |
cytochrome P450, family 27, subfamily b, polypeptide 1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP27B1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 7:70,333,150...70,340,006
Ensembl chr 7:70,335,061...70,340,005
|
|
G |
Cyp2b1 |
cytochrome P450, family 2, subfamily b, polypeptide 1 |
decreases activity multiple interactions |
EXP ISO |
Dextran Sulfate results in decreased activity of CYP2B1 protein [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CYP2B10 mRNA [Dextran Sulfate results in decreased activity of CYP2B1 protein] which results in decreased chemical synthesis of hydroxybupropion |
CTD |
PMID:28438436 PMID:29950665 |
|
NCBI chr 7:99,142,431...99,183,540
Ensembl chr 7:99,142,450...99,181,783
|
|
G |
Cyp2b2 |
cytochrome P450, family 2, subfamily b, polypeptide 2 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP2B13 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 1:83,103,925...83,119,578
Ensembl chr 1:83,103,925...83,119,193
|
|
G |
Cyp2c24 |
cytochrome P450, family 2, subfamily c, polypeptide 24 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP2C55 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 1:258,074,797...258,139,176
Ensembl chr 1:258,074,860...258,139,176
|
|
G |
Cyp2c6v1 |
cytochrome P450, family 2, subfamily C, polypeptide 6, variant 1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP2C38 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 1:147,713,879...147,814,410
Ensembl chr 1:147,713,892...147,888,007
|
|
G |
Cyp2c79 |
cytochrome P450, family 2, subfamily c, polypeptide 79 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP2C29 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 1:147,236,480...147,307,988
|
|
G |
Cyp2d1 |
cytochrome P450, family 2, subfamily d, polypeptide 1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP2D10 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 7:123,625,641...123,630,045
Ensembl chr 7:123,625,590...123,638,765
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
decreases activity multiple interactions |
EXP |
Dextran Sulfate results in decreased activity of CYP2E1 protein [Dextran Sulfate results in decreased activity of CYP2E1 protein] which results in decreased chemical synthesis of 6-hydroxychlorzoxazone |
CTD |
PMID:28438436 |
|
NCBI chr 1:213,511,892...213,522,195
Ensembl chr 1:213,511,874...213,535,542
|
|
G |
Cyp2j4 |
cytochrome P450, family 2, subfamily j, polypeptide 4 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP2J9 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 5:119,546,458...119,564,843
Ensembl chr 5:119,546,461...119,564,846
|
|
G |
Cyp2r1 |
cytochrome P450, family 2, subfamily r, polypeptide 1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP2R1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 1:184,060,521...184,106,604
Ensembl chr 1:184,093,920...184,106,200
|
|
G |
Cyp2s1 |
cytochrome P450, family 2, subfamily s, polypeptide 1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP2S1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 1:82,595,211...82,610,350
Ensembl chr 1:82,595,211...82,610,350
|
|
G |
Cyp3a62 |
cytochrome P450, family 3, subfamily a, polypeptide 62 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP3A11 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr12:18,679,809...18,709,397
Ensembl chr12:18,678,594...18,709,397
|
|
G |
Cyp3a9 |
cytochrome P450, family 3, subfamily a, polypeptide 9 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP3A13 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr12:19,074,288...19,114,491
Ensembl chr12:19,074,583...19,114,399
|
|
G |
Cyp4b1 |
cytochrome P450, family 4, subfamily b, polypeptide 1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP4B1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 5:134,508,728...134,526,103
Ensembl chr 5:134,508,730...134,526,089
|
|
G |
Cyp4f1 |
cytochrome P450, family 4, subfamily f, polypeptide 1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP4F14 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 7:15,179,472...15,191,113
Ensembl chr 7:15,179,467...15,190,796
|
|
G |
Cyp4f39 |
cytochrome P450, family 4, subfamily f, polypeptide 39 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CYP4F39 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 7:14,435,024...14,514,960
Ensembl chr 7:14,441,476...14,515,212
|
|
G |
Cyp7a1 |
cytochrome P450 family 7 subfamily A member 1 |
decreases expression |
ISO |
Dextran Sulfate results in decreased expression of CYP7A1 mRNA |
CTD |
PMID:27580383 |
|
NCBI chr 5:19,358,734...19,368,431
Ensembl chr 5:19,358,734...19,368,431
|
|
G |
Cyp7b1 |
cytochrome P450 family 7 subfamily B member 1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CYP7B1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 2:102,701,903...102,871,257
Ensembl chr 2:102,701,903...102,871,257
|
|
G |
Dbt |
dihydrolipoamide branched chain transacylase E2 |
decreases expression multiple interactions |
ISO |
Dextran Sulfate results in decreased expression of DBT protein Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of DBT protein] |
CTD |
PMID:32272095 |
|
NCBI chr 2:219,563,783...219,592,651
Ensembl chr 2:219,563,783...219,592,650
|
|
G |
Dcn |
decorin |
multiple interactions increases expression |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of DCN mRNA; Erianin inhibits the reaction [Dextran Sulfate results in increased expression of DCN protein] |
CTD |
PMID:29950665 PMID:32272095 |
|
NCBI chr 7:38,742,250...38,782,282
Ensembl chr 7:38,742,051...38,782,323
|
|
G |
Ddr2 |
discoidin domain receptor tyrosine kinase 2 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of DDR2 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr13:88,311,639...88,436,561
Ensembl chr13:88,317,145...88,436,789
|
|
G |
Derl3 |
derlin 3 |
increases expression |
ISO |
Dextran Sulfate results in increased expression of DERL3 mRNA |
CTD |
PMID:23894361 |
|
NCBI chr20:13,692,102...13,707,645
Ensembl chr20:13,704,314...13,706,205
|
|
G |
Dgkb |
diacylglycerol kinase, beta |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of DGKB mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 6:57,516,351...58,277,385
Ensembl chr 6:57,516,713...58,277,279
|
|
G |
Dgki |
diacylglycerol kinase, iota |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of DGKI mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 4:64,365,115...64,831,473
Ensembl chr 4:64,374,342...64,831,473
|
|
G |
Dhrs9 |
dehydrogenase/reductase 9 |
increases expression |
ISO |
Dextran Sulfate results in increased expression of DHRS9 mRNA |
CTD |
PMID:23894361 |
|
NCBI chr 3:55,623,671...55,645,883
Ensembl chr 3:55,623,634...55,648,325
|
|
G |
Dkk2 |
dickkopf WNT signaling pathway inhibitor 2 |
multiple interactions |
ISO |
[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of DKK2 mRNA; pristimerin inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of DKK2 mRNA] |
CTD |
PMID:31715269 |
|
NCBI chr 2:237,148,918...237,240,883
Ensembl chr 2:237,148,941...237,241,350
|
|
G |
Dlk1 |
delta like non-canonical Notch ligand 1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of DLK1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 6:133,576,513...133,583,751
Ensembl chr 6:133,552,821...133,583,751
|
|
G |
Dmpk |
DM1 protein kinase |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with Dextran Sulfate] results in increased expression of DMPK mRNA |
CTD |
PMID:26271895 |
|
NCBI chr 1:79,988,096...79,999,358
Ensembl chr 1:79,989,019...79,999,364
|
|
G |
Dnajc10 |
DnaJ heat shock protein family (Hsp40) member C10 |
increases expression multiple interactions |
ISO |
Dextran Sulfate results in increased expression of DNAJC10 protein Erianin inhibits the reaction [Dextran Sulfate results in increased expression of DNAJC10 protein] |
CTD |
PMID:32272095 |
|
NCBI chr 3:67,538,289...67,578,308
Ensembl chr 3:67,538,289...67,578,306
|
|
G |
Dnm1 |
dynamin 1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of DNM1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 3:11,338,081...11,382,043
Ensembl chr 3:11,338,083...11,382,043
|
|
G |
Dnm3 |
dynamin 3 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of DNM3 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr13:79,906,711...80,379,967
Ensembl chr13:79,910,382...80,379,929
|
|
G |
Dok2 |
docking protein 2 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of DOK2 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr15:52,449,884...52,455,414
Ensembl chr15:52,451,161...52,456,409
|
|
G |
Dpep1 |
dipeptidase 1 |
increases expression multiple interactions |
ISO |
Dextran Sulfate results in increased expression of DPEP1 protein Erianin inhibits the reaction [Dextran Sulfate results in increased expression of DPEP1 protein] |
CTD |
PMID:32272095 |
|
NCBI chr19:55,973,447...55,998,830
Ensembl chr19:55,982,740...55,998,208
|
|
G |
Dpep2 |
dipeptidase 2 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of DPEP2 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr19:37,964,098...37,975,154
Ensembl chr19:37,964,105...37,970,537
|
|
G |
Dpyd |
dihydropyrimidine dehydrogenase |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of DPYD mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 2:221,823,692...222,694,627
Ensembl chr 2:221,823,687...222,694,627
|
|
G |
Drd4 |
dopamine receptor D4 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of DRD4 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 1:214,278,296...214,282,818
Ensembl chr 1:214,278,296...214,281,483
|
|
G |
Drd5 |
dopamine receptor D5 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of DRD5 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr14:77,220,579...77,222,006
Ensembl chr14:77,220,579...77,222,006
|
|
G |
Dtx1 |
deltex E3 ubiquitin ligase 1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of DTX1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr12:41,383,885...41,415,783
Ensembl chr12:41,385,241...41,414,754
|
|
G |
Duoxa2 |
dual oxidase maturation factor 2 |
increases expression |
ISO |
Dextran Sulfate results in increased expression of DUOXA2 mRNA |
CTD |
PMID:23894361 |
|
NCBI chr 3:114,236,718...114,240,086
Ensembl chr 3:114,236,718...114,240,086
|
|
G |
Dusp1 |
dual specificity phosphatase 1 |
multiple interactions |
ISO |
DUSP1 protein affects the reaction [Butylated Hydroxyanisole affects the reaction [Dextran Sulfate affects the expression of IL6 protein]]; DUSP1 protein affects the reaction [Butylated Hydroxyanisole affects the reaction [Dextran Sulfate affects the expression of TNF protein]]; DUSP1 protein affects the reaction [Butylated Hydroxyanisole inhibits the reaction [Dextran Sulfate results in increased expression of PTGS2 protein]]; DUSP1 protein affects the reaction [Resveratrol affects the reaction [Dextran Sulfate affects the expression of IL6 protein]]; DUSP1 protein affects the reaction [Resveratrol affects the reaction [Dextran Sulfate affects the expression of TNF protein]]; DUSP1 protein affects the reaction [Resveratrol inhibits the reaction [Dextran Sulfate results in increased expression of PTGS2 protein]]; DUSP1 protein affects the susceptibility to [Azoxymethane co-treated with Dextran Sulfate] |
CTD |
PMID:30844440 |
|
NCBI chr10:16,970,642...16,973,425
Ensembl chr10:16,970,626...16,973,418
|
|
G |
Eci1 |
enoyl-CoA delta isomerase 1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ECI1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr10:13,797,573...13,810,918
Ensembl chr10:13,797,562...13,810,913
|
|
G |
Ecpas |
Ecm29 proteasome adaptor and scaffold |
decreases expression multiple interactions |
ISO |
Dextran Sulfate results in decreased expression of ECPAS protein Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of ECPAS protein] |
CTD |
PMID:32272095 |
|
NCBI chr 5:75,928,510...76,040,771
Ensembl chr 5:75,931,293...76,039,760
|
|
G |
Eda |
ectodysplasin-A |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of EDA mRNA |
CTD |
PMID:29950665 |
|
NCBI chr X:69,730,123...70,222,693
Ensembl chr X:69,730,242...70,220,329
|
|
G |
Eda2r |
ectodysplasin A2 receptor |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of EDA2R mRNA |
CTD |
PMID:29950665 |
|
NCBI chr X:66,560,200...66,602,509
Ensembl chr X:66,561,286...66,602,506
|
|
G |
Edn1 |
endothelin 1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of EDN1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr17:22,136,814...22,143,745
Ensembl chr17:22,137,324...22,143,324
|
|
G |
Edn2 |
endothelin 2 |
increases expression multiple interactions |
ISO |
Dextran Sulfate results in increased expression of EDN2 protein [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of EDN2 mRNA |
CTD |
PMID:16216902 PMID:29950665 |
|
NCBI chr 5:139,098,472...139,106,396
Ensembl chr 5:139,100,898...139,105,792
|
|
G |
Ednra |
endothelin receptor type A |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of EDNRA mRNA |
CTD |
PMID:29950665 |
|
NCBI chr19:33,928,356...33,991,703
Ensembl chr19:33,928,356...33,991,703
|
|
G |
Efemp2 |
EGF containing fibulin extracellular matrix protein 2 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of EFEMP2 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 1:220,853,695...220,861,420
Ensembl chr 1:220,854,403...220,861,420
|
|
G |
Efna1 |
ephrin A1 |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with Dextran Sulfate] results in decreased expression of EFNA1 mRNA |
CTD |
PMID:26271895 |
|
NCBI chr 2:188,588,808...188,596,156
Ensembl chr 2:188,588,796...188,596,222
|
|
G |
Ehhadh |
enoyl-CoA hydratase and 3-hydroxyacyl CoA dehydrogenase |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of EHHADH mRNA |
CTD |
PMID:29950665 |
|
NCBI chr11:82,945,104...82,978,364
Ensembl chr11:82,945,104...82,978,364
|
|
G |
Eif2ak2 |
eukaryotic translation initiation factor 2-alpha kinase 2 |
multiple interactions increases phosphorylation |
ISO |
EIF2AK2 protein affects the reaction [Dextran Sulfate results in increased activity of CASP3 protein]; EIF2AK2 protein affects the reaction [Dextran Sulfate results in increased expression of IL6 mRNA]; EIF2AK2 protein affects the reaction [Dextran Sulfate results in increased expression of NOS2 mRNA]; EIF2AK2 protein affects the reaction [Dextran Sulfate results in increased phosphorylation of RELA protein]; GW 506033X inhibits the reaction [Dextran Sulfate results in increased phosphorylation of EIF2AK2 protein] |
CTD |
PMID:27920257 |
|
NCBI chr 6:1,428,845...1,466,193
Ensembl chr 6:1,428,834...1,466,201
|
|
G |
Eif3a |
eukaryotic translation initiation factor 3, subunit A |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with Dextran Sulfate] results in increased expression of EIF3A mRNA |
CTD |
PMID:26271895 |
|
NCBI chr 1:282,139,809...282,170,017
Ensembl chr 1:282,139,823...282,170,017
|
|
G |
Elane |
elastase, neutrophil expressed |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ELANE mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 7:12,638,320...12,640,168
Ensembl chr 7:12,638,322...12,640,232
|
|
G |
Elmo2 |
engulfment and cell motility 2 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ELMO2 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 3:161,812,474...161,850,006
Ensembl chr 3:161,812,474...162,003,588
|
|
G |
Emc2 |
ER membrane protein complex subunit 2 |
multiple interactions decreases expression |
ISO |
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of EMC2 protein] |
CTD |
PMID:32272095 |
|
NCBI chr 7:82,338,639...82,377,389
Ensembl chr 7:82,338,663...82,377,109
|
|
G |
Eno3 |
enolase 3 |
multiple interactions decreases expression |
ISO |
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of ENO3 protein] |
CTD |
PMID:32272095 |
|
NCBI chr10:57,278,271...57,283,661
Ensembl chr10:57,278,307...57,283,653
|
|
G |
Enpep |
glutamyl aminopeptidase |
multiple interactions increases expression |
ISO |
Erianin inhibits the reaction [Dextran Sulfate results in increased expression of ENPEP protein] |
CTD |
PMID:32272095 |
|
NCBI chr 2:233,667,253...233,743,866
Ensembl chr 2:233,667,254...233,743,866
|
|
G |
Entpd5 |
ectonucleoside triphosphate diphosphohydrolase 5 |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with Dextran Sulfate] results in decreased expression of ENTPD5 mRNA |
CTD |
PMID:26271895 |
|
NCBI chr 6:108,087,677...108,123,811
Ensembl chr 6:108,087,418...108,120,579
|
|
G |
Ep300 |
E1A binding protein p300 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of EP300 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 7:122,818,194...122,889,055
Ensembl chr 7:122,818,975...122,861,296
|
|
G |
Erbb2 |
erb-b2 receptor tyrosine kinase 2 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ERBB2 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr10:86,367,596...86,391,728
Ensembl chr10:86,367,596...86,391,728
|
|
G |
Erbb3 |
erb-b2 receptor tyrosine kinase 3 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ERBB3 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 7:2,989,202...3,010,610
Ensembl chr 7:2,989,340...3,010,350
|
|
G |
Erbb4 |
erb-b2 receptor tyrosine kinase 4 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ERBB4 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 9:75,021,790...76,178,936
Ensembl chr 9:75,021,790...75,528,644
|
|
G |
Ereg |
epiregulin |
decreases response to substance increases expression |
ISO |
EREG protein results in decreased susceptibility to Dextran Sulfate dextran sodium sulfate increases expression of Ereg protein in colonic mucosa |
CTD |
PMID:15456865, PMID:20498653 |
RGD:39457688 |
NCBI chr14:18,577,620...18,591,395
Ensembl chr14:18,576,355...18,591,394
|
|
G |
Esam |
endothelial cell adhesion molecule |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ESAM mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 8:39,997,875...40,008,802
Ensembl chr 8:39,997,875...40,008,809
|
|
G |
Esr1 |
estrogen receptor 1 |
decreases expression multiple interactions |
ISO |
Dextran Sulfate results in decreased expression of ESR1 mRNA [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ESR1 mRNA |
CTD |
PMID:29950665 PMID:30270565 |
|
NCBI chr 1:41,192,029...41,594,799
Ensembl chr 1:41,192,824...41,594,796
|
|
G |
Esr2 |
estrogen receptor 2 |
multiple interactions |
ISO |
Dextran Sulfate promotes the reaction [Zearalenone results in increased expression of ESR2 mRNA] |
CTD |
PMID:30270565 |
|
NCBI chr 6:99,163,953...99,214,711
Ensembl chr 6:99,164,357...99,214,251
|
|
G |
Evl |
Enah/Vasp-like |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of EVL mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 6:132,470,283...132,590,242
Ensembl chr 6:132,510,757...132,590,241
|
|
G |
F10 |
coagulation factor X |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of F10 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr16:81,803,169...81,822,476
Ensembl chr16:81,803,110...81,822,716
|
|
G |
F13a1 |
coagulation factor XIII A1 chain |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of F13A1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr17:28,504,650...28,680,015
Ensembl chr17:28,504,623...28,680,362
|
|
G |
F2r |
coagulation factor II (thrombin) receptor |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of F2R mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 2:26,118,760...26,135,340
Ensembl chr 2:26,118,760...26,135,340
|
|
G |
F2rl1 |
F2R like trypsin receptor 1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of F2RL1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 2:25,222,324...25,235,275
Ensembl chr 2:25,222,328...25,235,275
|
|
G |
F5 |
coagulation factor V |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of F5 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr13:82,479,997...82,535,540
Ensembl chr13:82,479,998...82,535,534
|
|
G |
Faah |
fatty acid amide hydrolase |
multiple interactions |
ISO |
[Serotonin co-treated with Dextran Sulfate] results in decreased expression of FAAH protein |
CTD |
PMID:30611738 |
|
NCBI chr 5:134,852,899...134,872,095
Ensembl chr 5:134,852,875...134,871,775
|
|
G |
Faahl |
fatty-acid amide hydrolase-like |
multiple interactions |
ISO |
[Serotonin co-treated with Dextran Sulfate] results in decreased expression of FAAH protein |
CTD |
PMID:30611738 |
|
NCBI chr 5:134,330,204...134,349,400
Ensembl chr 5:134,331,929...134,348,995
|
|
G |
Fabp4 |
fatty acid binding protein 4 |
multiple interactions increases expression |
ISO |
[Benzo(a)pyrene co-treated with Dextran Sulfate] results in increased expression of FABP4 mRNA; Erianin inhibits the reaction [Dextran Sulfate results in increased expression of FABP4 protein] |
CTD |
PMID:26271895 PMID:32272095 |
|
NCBI chr 2:93,792,666...93,797,267
Ensembl chr 2:93,792,601...93,797,305
|
|
G |
Fabp6 |
fatty acid binding protein 6 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of FABP6 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr10:29,191,621...29,196,593
Ensembl chr10:29,191,623...29,196,563
|
|
G |
Fau |
FAU, ubiquitin like and ribosomal protein S30 fusion |
multiple interactions decreases expression |
ISO |
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of FAU protein] |
CTD |
PMID:32272095 |
|
NCBI chr 1:221,420,312...221,421,827
Ensembl chr 1:221,420,271...221,421,842
|
|
G |
Fbln2 |
fibulin 2 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FBLN2 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 4:122,835,237...122,895,127
Ensembl chr 4:122,835,436...122,895,121
|
|
G |
Fbln5 |
fibulin 5 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FBLN5 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 6:125,644,797...125,723,957
Ensembl chr 6:125,644,804...125,723,944
|
|
G |
Fbn1 |
fibrillin 1 |
multiple interactions decreases expression |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FBN1 mRNA; Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of FBN1 protein] |
CTD |
PMID:29950665 PMID:32272095 |
|
NCBI chr 3:117,569,708...117,766,160
Ensembl chr 3:117,569,697...117,766,120
|
|
G |
Fcer1g |
Fc fragment of IgE receptor Ig |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FCER1G mRNA |
CTD |
PMID:29950665 |
|
NCBI chr13:89,601,894...89,606,326
Ensembl chr13:89,601,896...89,606,326
|
|
G |
Fcgr1a |
Fc fragment of IgG receptor Ia |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FCGR1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 2:198,430,536...198,439,453
Ensembl chr 2:198,430,530...198,458,041
|
|
G |
Fcgr2a |
Fc fragment of IgG receptor IIa |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FCGR3 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr13:91,146,878...91,163,691
Ensembl chr13:91,168,973...91,198,036 Ensembl chr13:91,168,973...91,198,036
|
|
G |
Fcgr2b |
Fc fragment of IgG receptor IIb |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FCGR2B mRNA |
CTD |
PMID:29950665 |
|
NCBI chr13:89,329,298...89,343,916
Ensembl chr13:89,327,794...89,433,815
|
|
G |
Fcgr3a |
Fc fragment of IgG receptor IIIa |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FCGR4 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr13:89,385,775...89,396,047
Ensembl chr13:89,385,859...89,396,051
|
|
G |
Fdx1 |
ferredoxin 1 |
multiple interactions decreases expression |
ISO |
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of FDX1 protein] |
CTD |
PMID:32272095 |
|
NCBI chr 8:56,373,729...56,393,199
Ensembl chr 8:56,373,723...56,393,233
|
|
G |
Fermt3 |
fermitin family member 3 |
increases expression multiple interactions |
ISO |
Dextran Sulfate results in increased expression of FERMT3 protein Erianin inhibits the reaction [Dextran Sulfate results in increased expression of FERMT3 protein] |
CTD |
PMID:32272095 |
|
NCBI chr 1:222,254,183...222,272,775
Ensembl chr 1:222,254,184...222,272,285
|
|
G |
Ffar2 |
free fatty acid receptor 2 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of FFAR2 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 1:89,268,197...89,271,942
Ensembl chr 1:89,268,938...89,269,930
|
|
G |
Ffar4 |
free fatty acid receptor 4 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of FFAR4 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 1:256,786,124...256,804,156
Ensembl chr 1:256,786,124...256,804,156
|
|
G |
Fgf18 |
fibroblast growth factor 18 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FGF18 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr10:18,047,109...18,082,290
Ensembl chr10:18,047,109...18,063,391
|
|
G |
Fgf19 |
fibroblast growth factor 19 |
multiple interactions |
ISO |
Dextran Sulfate results in increased expression of and results in increased secretion of FGF15 protein |
CTD |
PMID:27580383 |
|
NCBI chr 1:218,058,405...218,061,693
Ensembl chr 1:218,058,405...218,061,693
|
|
G |
Fgf2 |
fibroblast growth factor 2 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FGF2 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 2:124,081,072...124,134,133
Ensembl chr 2:124,081,072...124,134,681
|
|
G |
Fgf23 |
fibroblast growth factor 23 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of FGF23 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 4:159,622,404...159,630,082
Ensembl chr 4:159,622,404...159,630,082
|
|
G |
Fgf8 |
fibroblast growth factor 8 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of FGF8 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 1:265,492,949...265,498,965
Ensembl chr 1:265,493,124...265,498,831
|
|
G |
Fgf9 |
fibroblast growth factor 9 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of FGF9 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr15:38,341,657...38,386,945
Ensembl chr15:38,341,089...38,387,316
|
|
G |
Fgfr1 |
Fibroblast growth factor receptor 1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FGFR1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr16:71,265,390...71,319,046
Ensembl chr16:71,266,248...71,319,449
|
|
G |
Fgfr4 |
fibroblast growth factor receptor 4 |
increases expression |
ISO |
Dextran Sulfate results in increased expression of FGFR4 mRNA |
CTD |
PMID:27580383 |
|
NCBI chr17:9,990,072...10,004,339
Ensembl chr17:9,990,078...10,004,321
|
|
G |
Fhl3 |
four and a half LIM domains 3 |
increases expression multiple interactions |
ISO |
Dextran Sulfate results in increased expression of FHL3 protein Erianin inhibits the reaction [Dextran Sulfate results in increased expression of FHL3 protein] |
CTD |
PMID:32272095 |
|
NCBI chr 5:142,688,962...142,696,330
Ensembl chr 5:142,689,026...142,696,383
|
|
G |
Flot2 |
flotillin 2 |
increases expression multiple interactions |
ISO |
Dextran Sulfate results in increased expression of FLOT2 protein Erianin inhibits the reaction [Dextran Sulfate results in increased expression of FLOT2 protein] |
CTD |
PMID:32272095 |
|
NCBI chr10:65,304,901...65,329,332
Ensembl chr10:65,304,902...65,329,312
|
|
G |
Flt1 |
Fms related receptor tyrosine kinase 1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FLT1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr12:9,033,993...9,205,886
Ensembl chr12:9,034,308...9,205,905
|
|
G |
Flt4 |
Fms related receptor tyrosine kinase 4 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FLT4 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr10:35,078,782...35,120,296
Ensembl chr10:35,078,726...35,121,599
|
|
G |
Fmo1 |
flavin containing dimethylaniline monoxygenase 1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FMO1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr13:80,712,885...80,745,095
Ensembl chr13:80,712,882...80,745,347
|
|
G |
Fmod |
fibromodulin |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FMOD mRNA |
CTD |
PMID:29950665 |
|
NCBI chr13:50,874,886...50,885,503
Ensembl chr13:50,873,605...50,885,563
|
|
G |
Fn1 |
fibronectin 1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FN1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 9:78,900,111...78,969,018
Ensembl chr 9:78,900,103...78,969,078
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
ISO |
Dextran Sulfate promotes the reaction [Capsaicin results in increased expression of FOS protein]; GRK6 mutant form promotes the reaction [Dextran Sulfate promotes the reaction [Capsaicin results in increased expression of FOS protein]] |
CTD |
PMID:18687398 |
|
NCBI chr 6:109,300,433...109,303,299
Ensembl chr 6:109,300,433...109,303,299
|
|
G |
Fosl1 |
FOS like 1, AP-1 transcription factor subunit |
increases expression |
ISO |
Dextran Sulfate results in increased expression of FOSL1 protein |
CTD |
PMID:20025956 |
|
NCBI chr 1:220,826,560...220,835,066
Ensembl chr 1:220,826,560...220,835,066
|
|
G |
Foxa2 |
forkhead box A2 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of FOXA2 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 3:142,383,084...142,387,493
Ensembl chr 3:142,383,278...142,387,481
|
|
G |
Foxa3 |
forkhead box A3 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of FOXA3 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 1:79,921,292...79,930,219
Ensembl chr 1:79,920,752...79,930,263
|
|
G |
Foxo3 |
forkhead box O3 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of FOXO3 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr20:46,428,078...46,519,156
Ensembl chr20:46,428,124...46,519,144
|
|
G |
Foxo4 |
forkhead box O4 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FOXO4 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr X:71,155,284...71,162,158
Ensembl chr X:71,155,601...71,162,158
|
|
G |
Foxp3 |
forkhead box P3 |
increases methylation increases expression multiple interactions |
ISO EXP |
Dextran Sulfate results in increased methylation of FOXP3 gene Dextran Sulfate results in increased expression of FOXP3 mRNA kappa-casein glycomacropeptide inhibits the reaction [Dextran Sulfate results in increased expression of FOXP3 mRNA] Chlorpyrifos inhibits the reaction [Dextran Sulfate results in increased expression of FOXP3 mRNA]; Tetrachlorodibenzodioxin inhibits the reaction [Dextran Sulfate results in increased methylation of FOXP3 gene] |
CTD |
PMID:20881082 PMID:21858153 PMID:31807802 |
|
NCBI chr X:15,753,175...15,768,648
Ensembl chr X:15,753,175...15,768,522
|
|
G |
Fpgt |
fucose-1-phosphate guanylyltransferase |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of FPGT mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 2:261,382,015...261,402,950
Ensembl chr 2:261,382,060...261,402,903
|
|
G |
Fpr1 |
formyl peptide receptor 1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FPR1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 1:59,759,025...59,767,258
Ensembl chr 1:59,765,835...59,767,042
|
|
G |
Fpr2 |
formyl peptide receptor 2 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FPR2 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 1:59,800,558...59,809,507
Ensembl chr 1:59,800,984...59,802,401
|
|
G |
Fpr3 |
formyl peptide receptor 3 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of FPR3 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 1:116,152,526...116,161,873
Ensembl chr 1:116,152,667...116,153,722
|
|
G |
Fshr |
follicle stimulating hormone receptor |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FSHR mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 6:12,796,383...12,997,817
Ensembl chr 6:12,796,383...12,997,817
|
|
G |
Fst |
follistatin |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FST mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 2:46,537,589...46,544,813
Ensembl chr 2:46,538,700...46,544,457
|
|
G |
Fstl3 |
follistatin like 3 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FSTL3 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 7:12,806,031...12,810,556
Ensembl chr 7:12,804,919...12,810,570
|
|
G |
Fxyd1 |
FXYD domain-containing ion transport regulator 1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FXYD1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 1:89,484,197...89,488,279
Ensembl chr 1:89,484,199...89,488,223
|
|
G |
Fxyd3 |
FXYD domain-containing ion transport regulator 3 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FXYD3 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 1:89,502,561...89,510,146
Ensembl chr 1:89,502,562...89,509,343
|
|
G |
Fxyd4 |
FXYD domain-containing ion transport regulator 4 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FXYD4 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 4:149,984,206...149,988,744
Ensembl chr 4:149,984,206...149,988,295
|
|
G |
Fyn |
FYN proto-oncogene, Src family tyrosine kinase |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FYN mRNA |
CTD |
PMID:29950665 |
|
NCBI chr20:44,436,354...44,630,316
Ensembl chr20:44,436,403...44,630,317
|
|
G |
Fzd1 |
frizzled class receptor 1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FZD1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 4:26,470,864...26,475,262
Ensembl chr 4:26,470,864...26,475,262
|
|
G |
Fzd4 |
frizzled class receptor 4 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FZD4 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 1:153,589,471...153,598,376
Ensembl chr 1:153,589,471...153,598,375
|
|
G |
Fzd5 |
frizzled class receptor 5 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of FZD5 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 9:71,443,784...71,445,541
Ensembl chr 9:71,443,588...71,445,739
|
|
G |
Fzd6 |
frizzled class receptor 6 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FZD6 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 7:77,898,329...77,931,034
Ensembl chr 7:77,899,322...77,931,029
|
|
G |
Fzd7 |
frizzled class receptor 7 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FZD7 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 9:66,305,731...66,308,550
Ensembl chr 9:66,305,731...66,308,550
|
|
G |
Fzd8 |
frizzled class receptor 8 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of FZD8 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr17:62,259,910...62,267,239
Ensembl chr17:62,262,129...62,265,113
|
|
G |
G6pc1 |
glucose-6-phosphatase catalytic subunit 1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of G6PC1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr10:89,286,009...89,296,213
Ensembl chr10:89,285,855...89,296,213
|
|
G |
Gabbr1 |
gamma-aminobutyric acid type B receptor subunit 1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GABBR1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr20:1,955,344...1,984,907
Ensembl chr20:1,955,359...1,984,863
|
|
G |
Gabra2 |
gamma-aminobutyric acid type A receptor subunit alpha 2 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GABRA2 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr14:39,662,411...39,801,082
Ensembl chr14:39,661,968...39,798,302
|
|
G |
Gabra5 |
gamma-aminobutyric acid type A receptor subunit alpha 5 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GABRA5 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 1:112,833,941...112,947,482
Ensembl chr 1:112,833,944...112,947,451
|
|
G |
Gabrb2 |
gamma-aminobutyric acid type A receptor subunit beta 2 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GABRB2 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr10:27,973,694...28,193,072
Ensembl chr10:27,973,681...28,187,565
|
|
G |
Gabrd |
gamma-aminobutyric acid type A receptor subunit delta |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GABRD mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 5:172,797,478...172,809,374
Ensembl chr 5:172,797,450...172,809,353
|
|
G |
Gad1 |
glutamate decarboxylase 1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GAD1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 3:56,861,440...56,902,139
Ensembl chr 3:56,861,396...56,902,157
|
|
G |
Gale |
UDP-galactose-4-epimerase |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GALE mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 5:154,310,453...154,314,959
Ensembl chr 5:154,310,453...154,314,955
|
|
G |
Galk2 |
galactokinase 2 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GALK2 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 3:118,137,097...118,268,838
Ensembl chr 3:118,136,838...118,268,836
|
|
G |
Galnt10 |
polypeptide N-acetylgalactosaminyltransferase 10 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GALNT10 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr10:43,067,316...43,208,992
Ensembl chr10:43,067,299...43,210,427
|
|
G |
Galnt12 |
polypeptide N-acetylgalactosaminyltransferase 12 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GALNT12 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 5:62,718,733...62,751,345
Ensembl chr 5:62,718,787...62,750,145
|
|
G |
Galnt15 |
polypeptide N-acetylgalactosaminyltransferase 15 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GALNT15 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr16:8,127,599...8,178,101
Ensembl chr16:8,128,689...8,177,841
|
|
G |
Galnt16 |
polypeptide N-acetylgalactosaminyltransferase 16 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GALNT16 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 6:104,069,853...104,250,177
Ensembl chr 6:104,068,547...104,250,174
|
|
G |
Galnt18 |
polypeptide N-acetylgalactosaminyltransferase 18 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GALNT18 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 1:176,296,186...176,607,466
Ensembl chr 1:176,296,193...176,607,466
|
|
G |
Galnt2 |
polypeptide N-acetylgalactosaminyltransferase 2 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GALNT2 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr19:57,043,858...57,115,123
Ensembl chr19:57,047,830...57,115,132
|
|
G |
Galnt4 |
polypeptide N-acetylgalactosaminyltransferase 4 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GALNT4 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 7:41,305,437...41,309,621
|
|
G |
Galnt5 |
polypeptide N-acetylgalactosaminyltransferase 5 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GALNT5 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 3:44,025,964...44,072,073
Ensembl chr 3:44,025,300...44,074,678
|
|
G |
Galnt6 |
polypeptide N-acetylgalactosaminyltransferase 6 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GALNT6 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 7:142,322,172...142,364,281
Ensembl chr 7:142,322,172...142,352,382
|
|
G |
Galnt7 |
polypeptide N-acetylgalactosaminyltransferase 7 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GALNT7 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr16:35,935,059...36,062,734
Ensembl chr16:35,934,970...36,062,719
|
|
G |
Galntl6 |
polypeptide N-acetylgalactosaminyltransferase-like 6 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GALNTL6 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr16:34,551,052...35,803,840
Ensembl chr16:35,573,058...35,802,979
|
|
G |
Gast |
gastrin |
decreases response to substance multiple interactions |
ISO |
GAST protein modified form results in decreased susceptibility to Dextran Sulfate [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GAST mRNA |
CTD |
PMID:16618411 PMID:29950665 |
|
NCBI chr10:88,245,532...88,248,485
Ensembl chr10:88,245,532...88,248,484
|
|
G |
Gata2 |
GATA binding protein 2 |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with Dextran Sulfate] results in increased expression of GATA2 mRNA |
CTD |
PMID:26271895 |
|
NCBI chr 4:120,129,028...120,142,490
Ensembl chr 4:120,133,713...120,142,488
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GCLC mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 8:85,059,051...85,097,471
Ensembl chr 8:85,059,051...85,097,468
|
|
G |
Gclm |
glutamate cysteine ligase, modifier subunit |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GCLM mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 2:225,827,504...225,847,876
Ensembl chr 2:225,827,504...225,847,874
|
|
G |
Gcnt3 |
glucosaminyl (N-acetyl) transferase 3, mucin type |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GCNT3 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 8:76,449,078...76,459,431
Ensembl chr 8:76,449,081...76,452,554
|
|
G |
Gfpt1 |
glutamine fructose-6-phosphate transaminase 1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GFPT1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 4:118,852,046...118,901,583
Ensembl chr 4:118,852,062...118,901,591
|
|
G |
Gfpt2 |
glutamine-fructose-6-phosphate transaminase 2 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GFPT2 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr10:35,279,237...35,325,506
Ensembl chr10:35,279,236...35,325,508
|
|
G |
Gfus |
GDP-L-fucose synthase |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GFUS mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 7:116,958,427...116,963,281
Ensembl chr 7:116,958,392...116,963,295
|
|
G |
Ggct |
gamma-glutamyl cyclotransferase |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GGCT mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 4:85,186,644...85,192,857
Ensembl chr 4:85,186,644...85,192,834
|
|
G |
Gh1 |
growth hormone 1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GH mRNA |
CTD |
PMID:29950665 |
|
NCBI chr10:94,486,204...94,488,181
Ensembl chr10:94,486,205...94,488,180
|
|
G |
Ghrl |
ghrelin and obestatin prepropeptide |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GHRL mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 4:145,674,157...145,678,066
Ensembl chr 4:145,674,157...145,678,066
|
|
G |
Glb1 |
galactosidase, beta 1 |
increases expression multiple interactions |
ISO |
Dextran Sulfate results in increased expression of GLB1 protein Erianin inhibits the reaction [Dextran Sulfate results in increased expression of GLB1 protein] |
CTD |
PMID:32272095 |
|
NCBI chr 8:122,439,328...122,511,939
Ensembl chr 8:122,439,328...122,511,939
|
|
G |
Gli3 |
GLI family zinc finger 3 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GLI3 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr17:52,294,942...52,569,036
Ensembl chr17:52,294,942...52,569,036
|
|
G |
Glp1r |
glucagon-like peptide 1 receptor |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GLP1R mRNA |
CTD |
PMID:29950665 |
|
NCBI chr20:9,586,075...9,626,228
Ensembl chr20:9,586,075...9,626,228
|
|
G |
Gls |
glutaminase |
decreases expression multiple interactions |
ISO |
Dextran Sulfate results in decreased expression of GLS protein Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of GLS protein] |
CTD |
PMID:32272095 |
|
NCBI chr 9:54,212,622...54,284,879
Ensembl chr 9:54,212,767...54,284,872
|
|
G |
Gmds |
GDP-mannose 4, 6-dehydratase |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GMDS mRNA |
CTD |
PMID:29950665 |
|
NCBI chr17:33,408,722...33,938,086
Ensembl chr17:33,408,722...33,938,085
|
|
G |
Gna11 |
G protein subunit alpha 11 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GNA11 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 7:11,033,400...11,047,284
Ensembl chr 7:11,033,317...11,047,437
|
|
G |
Gna12 |
G protein subunit alpha 12 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GNA12 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr12:15,890,202...15,971,212
Ensembl chr12:15,890,170...15,971,212
|
|
G |
Gna14 |
G protein subunit alpha 14 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GNA14 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 1:235,165,775...235,347,986
Ensembl chr 1:235,166,718...235,347,937
|
|
G |
Gna15 |
G protein subunit alpha 15 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GNA15 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 7:11,054,249...11,075,152
Ensembl chr 7:11,054,333...11,077,251
|
|
G |
Gnaz |
G protein subunit alpha z |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GNAZ mRNA |
CTD |
PMID:29950665 |
|
NCBI chr20:14,593,072...14,644,020
Ensembl chr20:14,593,819...14,620,019
|
|
G |
Gnb3 |
G protein subunit beta 3 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GNB3 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 4:157,352,558...157,359,237
Ensembl chr 4:157,352,372...157,358,262
|
|
G |
Gne |
glucosamine (UDP-N-acetyl)-2-epimerase/N-acetylmannosamine kinase |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GNE mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 5:59,511,738...59,553,421
Ensembl chr 5:59,512,872...59,553,416
|
|
G |
Gng4 |
G protein subunit gamma 4 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GNG4 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr17:90,266,571...90,316,278
Ensembl chr17:90,266,794...90,315,492
|
|
G |
Gng7 |
G protein subunit gamma 7 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GNG7 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 7:11,565,740...11,629,519
Ensembl chr 7:11,582,984...11,628,929
|
|
G |
Gng8 |
G protein subunit gamma 8 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GNG8 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 1:78,818,360...78,822,224
Ensembl chr 1:78,818,404...78,822,224
|
|
G |
Gngt2 |
G protein subunit gamma transducin 2 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GNGT2 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr10:83,654,321...83,658,601
Ensembl chr10:83,655,460...83,658,589
|
|
G |
Gnpnat1 |
glucosamine-phosphate N-acetyltransferase 1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GNPNAT1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr15:19,721,292...19,734,032
Ensembl chr15:19,721,293...19,733,967
|
|
G |
Gpbar1 |
G protein-coupled bile acid receptor 1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GPBAR1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 9:81,555,914...81,560,931
Ensembl chr 9:81,559,605...81,560,594
|
|
G |
Gpc4 |
glypican 4 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GPC4 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr X:139,354,325...139,464,876
Ensembl chr X:139,354,155...139,464,798
|
|
G |
Gpnmb |
glycoprotein nmb |
increases expression |
ISO |
Dextran Sulfate results in increased expression of GPNMB mRNA |
CTD |
PMID:23894361 |
|
NCBI chr 4:78,694,447...78,715,685
Ensembl chr 4:78,694,447...78,715,683
|
|
G |
Gpr119 |
G protein-coupled receptor 119 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] affects the expression of GPR119 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr X:135,515,545...135,521,598
Ensembl chr X:135,515,545...135,521,598
|
|
G |
Gpr137b |
G protein-coupled receptor 137B |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GPR137B mRNA |
CTD |
PMID:29950665 |
|
NCBI chr17:90,670,852...90,709,003
Ensembl chr17:90,670,872...90,746,804
|
|
G |
Gpr149 |
G protein-coupled receptor 149 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GPR149 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 2:152,838,836...152,912,027
Ensembl chr 2:152,839,117...152,911,553
|
|
G |
Gpr15 |
G protein-coupled receptor 15 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GPR15 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr11:43,992,739...44,004,189
Ensembl chr11:44,001,579...44,003,664
|
|
G |
Gpr152 |
G protein-coupled receptor 152 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GPR152 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 1:219,389,418...219,394,124
Ensembl chr 1:219,390,523...219,392,478
|
|
G |
Gpr17 |
G protein-coupled receptor 17 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GPR17 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr18:24,733,306...24,739,194
Ensembl chr18:24,734,330...24,735,349
|
|
G |
Gpr176 |
G protein-coupled receptor 176 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GPR176 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 3:110,042,853...110,140,756
Ensembl chr 3:110,042,853...110,140,756
|
|
G |
Gpr20 |
G protein-coupled receptor 20 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GPR20 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 7:114,943,675...114,953,977
Ensembl chr 7:114,944,282...114,945,344
|
|
G |
Gpr27 |
G protein-coupled receptor 27 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GPR27 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 4:132,137,793...132,138,926
Ensembl chr 4:132,137,793...132,138,926
|
|
G |
Gpr37l1 |
G protein-coupled receptor 37-like 1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GPR37L1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr13:51,985,698...51,992,547
Ensembl chr13:51,985,684...51,992,693
|
|
G |
Gpr39 |
G protein-coupled receptor 39 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GPR39 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr13:42,008,642...42,220,737
Ensembl chr13:42,008,842...42,009,738
|
|
G |
Gpr4 |
G protein-coupled receptor 4 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GPR4 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 1:80,125,639...80,136,786
Ensembl chr 1:80,135,391...80,136,880
|
|
G |
Gpr50 |
G protein-coupled receptor 50 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GPR50 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr17:36,771,578...36,776,225
Ensembl chr17:36,771,639...36,776,225
|
|
G |
Gpr68 |
G protein-coupled receptor 68 |
multiple interactions |
ISO |
[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GPR68 mRNA |
CTD |
PMID:28174749 |
|
NCBI chr 6:124,874,151...124,903,949
Ensembl chr 6:124,874,151...124,876,710
|
|
G |
Gpr83 |
G protein-coupled receptor 83 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GPR83 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 8:13,365,583...13,376,071
Ensembl chr 8:13,365,583...13,376,070
|
|
G |
Gpr85 |
G protein-coupled receptor 85 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GPR85 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 4:40,377,705...40,387,147
Ensembl chr 4:40,381,685...40,385,349
|
|
G |
Gpr88 |
G-protein coupled receptor 88 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GPR88 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 2:219,258,346...219,263,819
Ensembl chr 2:219,258,347...219,262,901
|
|
G |
Gprc5b |
G protein-coupled receptor, class C, group 5, member B |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GPRC5B mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 1:188,688,743...188,713,724
Ensembl chr 1:188,688,743...188,713,280
|
|
G |
Gprc5d |
G protein-coupled receptor, class C, group 5, member D |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GPRC5D mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 4:168,872,897...168,884,925
Ensembl chr 4:168,872,897...168,884,886
|
|
G |
Gpx3 |
glutathione peroxidase 3 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GPX3 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr10:40,247,436...40,255,423
Ensembl chr10:40,247,436...40,255,422
|
|
G |
Gpx7 |
glutathione peroxidase 7 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GPX7 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 5:128,001,766...128,009,610
Ensembl chr 5:128,001,761...128,009,735
|
|
G |
Gpx8 |
glutathione peroxidase 8 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GPX8 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 2:44,903,337...44,907,046
Ensembl chr 2:44,903,337...44,907,030
|
|
G |
Grb2 |
growth factor receptor bound protein 2 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GRB2 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr10:104,193,953...104,263,071
Ensembl chr10:104,193,955...104,263,071
|
|
G |
Grb7 |
growth factor receptor bound protein 7 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GRB7 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr10:86,393,186...86,408,893
Ensembl chr10:86,399,827...86,409,348
|
|
G |
Grem1 |
gremlin 1, DAN family BMP antagonist |
multiple interactions increases expression |
ISO |
Erianin inhibits the reaction [Dextran Sulfate results in increased expression of GREM1 protein] |
CTD |
PMID:32272095 |
|
NCBI chr 3:105,203,309...105,214,989
Ensembl chr 3:105,203,309...105,214,989
|
|
G |
Grik4 |
glutamate ionotropic receptor kainate type subunit 4 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GRIK4 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 8:46,804,134...47,237,546
Ensembl chr 8:46,806,147...47,094,352
|
|
G |
Grin2b |
glutamate ionotropic receptor NMDA type subunit 2B |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GRIN2B mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 4:169,541,620...170,000,216
Ensembl chr 4:169,560,387...169,999,873
|
|
G |
Grin2d |
glutamate ionotropic receptor NMDA type subunit 2D |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GRIN2D mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 1:101,819,068...101,859,146
Ensembl chr 1:101,820,461...101,856,881
|
|
G |
Grk3 |
G protein-coupled receptor kinase 3 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GRK3 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr12:49,626,871...49,750,389
Ensembl chr12:49,626,871...49,746,272
|
|
G |
Grk6 |
G protein-coupled receptor kinase 6 |
multiple interactions decreases response to substance |
ISO |
GRK6 mutant form promotes the reaction [Dextran Sulfate promotes the reaction [Capsaicin results in increased expression of FOS protein]] GRK6 results in decreased susceptibility to Dextran Sulfate |
CTD |
PMID:18687398 |
|
NCBI chr17:9,705,917...9,721,921
Ensembl chr17:9,703,453...9,721,574
|
|
G |
Grm4 |
glutamate metabotropic receptor 4 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GRM4 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr20:6,745,682...6,791,521
Ensembl chr20:6,745,682...6,791,519
|
|
G |
Grpr |
gastrin releasing peptide receptor |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GRPR mRNA |
CTD |
PMID:29950665 |
|
NCBI chr X:32,746,259...32,786,266
Ensembl chr X:32,745,873...32,786,359
|
|
G |
Gsn |
gelsolin |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GSN mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 3:14,456,106...14,508,922
Ensembl chr 3:14,467,330...14,508,911
|
|
G |
Gss |
glutathione synthetase |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GSS mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 3:151,076,254...151,106,557
Ensembl chr 3:151,076,254...151,106,557
|
|
G |
Gstk1 |
glutathione S-transferase kappa 1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GSTK1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 4:71,621,777...71,626,096
Ensembl chr 4:71,621,729...71,626,107
|
|
G |
Gstm5 |
glutathione S-transferase, mu 5 |
multiple interactions decreases expression |
ISO |
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of GSTM3 protein] |
CTD |
PMID:32272095 |
|
NCBI chr 2:210,685,338...210,688,133
Ensembl chr 2:210,685,197...210,688,272
|
|
G |
Gsto1 |
glutathione S-transferase omega 1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GSTO1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 1:267,607,437...267,617,387
Ensembl chr 1:267,607,418...267,617,387
|
|
G |
Gsto2 |
glutathione S-transferase omega 2 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GSTO2 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 1:267,617,517...267,640,455
Ensembl chr 1:271,229,036...271,243,517 Ensembl chr 1:271,229,036...271,243,517
|
|
G |
Gstt2 |
glutathione S-transferase, theta 2 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GSTT2 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr20:13,760,810...13,764,481
Ensembl chr20:13,760,810...13,764,475
|
|
G |
Guca1b |
guanylate cyclase activator 1B |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GUCA1B mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 9:15,621,083...15,629,017
Ensembl chr 9:15,621,083...15,629,017
|
|
G |
Gucy2f |
guanylate cyclase 2F |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GUCY2F mRNA |
CTD |
PMID:29950665 |
|
NCBI chr X:113,372,240...113,474,210
Ensembl chr X:113,372,240...113,474,164
|
|
G |
Guk1 |
guanylate kinase 1 |
multiple interactions decreases expression |
ISO |
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of GUK1 protein] |
CTD |
PMID:32272095 |
|
NCBI chr10:45,535,617...45,552,455
Ensembl chr10:45,535,627...45,543,897
|
|
G |
Gzma |
granzyme A |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GZMA mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 2:44,968,846...44,981,436
Ensembl chr 2:44,968,765...44,981,458
|
|
G |
Hadh |
hydroxyacyl-CoA dehydrogenase |
decreases expression multiple interactions |
ISO |
Dextran Sulfate results in decreased expression of HADH protein Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of HADH protein] |
CTD |
PMID:32272095 |
|
NCBI chr 2:236,353,445...236,395,067
Ensembl chr 2:236,353,445...236,395,067
|
|
G |
Hadhb |
hydroxyacyl-CoA dehydrogenase trifunctional multienzyme complex subunit beta |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of HADHB mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 6:27,555,408...27,589,539
Ensembl chr 6:27,555,412...27,582,995
|
|
G |
Hcar2 |
hydroxycarboxylic acid receptor 2 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of HCAR2 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr12:38,160,464...38,161,546
Ensembl chr12:38,160,464...38,161,546
|
|
G |
Hcn2 |
hyperpolarization activated cyclic nucleotide gated potassium and sodium channel 2 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of HCN2 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 7:12,851,730...12,870,087
Ensembl chr 7:12,851,739...12,874,215
|
|
G |
Hcn3 |
hyperpolarization-activated cyclic nucleotide-gated potassium channel 3 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of HCN3 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 2:188,458,851...188,471,916
Ensembl chr 2:188,454,853...188,471,988
|
|
G |
Hcn4 |
hyperpolarization activated cyclic nucleotide-gated potassium channel 4 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of HCN4 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 8:63,599,907...63,637,327
Ensembl chr 8:63,600,663...63,639,654
|
|
G |
Heph |
hephaestin |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of HEPH mRNA |
CTD |
PMID:29950665 |
|
NCBI chr X:65,377,313...65,658,479
Ensembl chr X:65,563,122...65,658,516
|
|
G |
Hes1 |
hes family bHLH transcription factor 1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] affects the expression of HES1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr11:74,312,837...74,315,249
Ensembl chr11:74,312,806...74,315,248
|
|
G |
Hif1a |
hypoxia inducible factor 1 subunit alpha |
increases expression multiple interactions |
ISO |
Dextran Sulfate results in increased expression of HIF1A protein resveratrol inhibits the reaction [Dextran Sulfate results in increased expression of HIF1A protein] |
CTD |
PMID:26074695 |
|
NCBI chr 6:96,810,868...96,856,303
Ensembl chr 6:96,810,907...96,856,052
|
|
G |
Hk3 |
hexokinase 3 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of HK3 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr17:10,134,726...10,152,976
Ensembl chr17:10,137,974...10,152,956
|
|
G |
Hmgb1 |
high mobility group box 1 |
multiple interactions |
ISO |
15,16-dihydrotanshinone I inhibits the reaction [Dextran Sulfate results in increased expression of and results in increased secretion of HMGB1 protein]; Dextran Sulfate results in increased expression of and results in increased secretion of HMGB1 protein |
CTD |
PMID:29496522 |
|
NCBI chr12:7,082,529...7,090,246
Ensembl chr16:37,500,017...37,502,237
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions decreases expression |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of HMOX1 mRNA; tussilagone inhibits the reaction [Dextran Sulfate results in decreased expression of HMOX1 mRNA]; tussilagone inhibits the reaction [Dextran Sulfate results in decreased expression of HMOX1 protein] Dextran Sulfate results in decreased expression of HMOX1 mRNA; Dextran Sulfate results in decreased expression of HMOX1 protein |
CTD |
PMID:29950665 PMID:30142311 |
|
NCBI chr19:14,508,634...14,515,455
Ensembl chr19:14,508,616...14,515,456
|
|
G |
Hnf1a |
HNF1 homeobox A |
increases expression multiple interactions |
ISO |
Dextran Sulfate results in increased expression of HNF1A protein 6-formylindolo(3,2-b)carbazole inhibits the reaction [Dextran Sulfate results in increased expression of HNF1A protein]; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of HNF1A mRNA |
CTD |
PMID:29680209 PMID:29950665 |
|
NCBI chr12:47,407,811...47,433,342
Ensembl chr12:47,407,811...47,433,342
|
|
G |
Hnf1b |
HNF1 homeobox B |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of HNF1B mRNA |
CTD |
PMID:29950665 |
|
NCBI chr10:71,159,863...71,218,902
Ensembl chr10:71,159,869...71,218,902
|
|
G |
Hnf4a |
hepatocyte nuclear factor 4, alpha |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of HNF4A mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 3:159,902,441...159,965,003
Ensembl chr 3:159,902,441...159,965,003
|
|
G |
Hnf4g |
hepatocyte nuclear factor 4, gamma |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of HNF4G mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 2:100,225,880...100,372,710
Ensembl chr 2:100,225,888...100,372,252
|
|
G |
Hp |
haptoglobin |
multiple interactions increases expression |
ISO |
Chlorpyrifos promotes the reaction [Dextran Sulfate results in increased expression of HP protein] |
CTD |
PMID:31807802 |
|
NCBI chr19:42,096,255...42,100,805
Ensembl chr19:42,097,995...42,100,804
|
|
G |
Hpgd |
15-hydroxyprostaglandin dehydrogenase |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of HPGD mRNA |
CTD |
PMID:29950665 |
|
NCBI chr16:37,457,134...37,495,758
Ensembl chr16:37,457,135...37,495,758
|
|
G |
Hrh3 |
histamine receptor H3 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of HRH3 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 3:175,474,310...175,479,395
Ensembl chr 3:175,473,078...175,479,395
|
|
G |
Hsd11b1 |
hydroxysteroid 11-beta dehydrogenase 1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of HSD11B1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr13:111,946,626...111,996,536
Ensembl chr13:111,926,442...111,972,603
|
|
G |
Hsd11b2 |
hydroxysteroid 11-beta dehydrogenase 2 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of HSD11B2 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr19:37,476,083...37,481,326
Ensembl chr19:37,476,095...37,481,307
|
|
G |
Hsd17b1 |
hydroxysteroid (17-beta) dehydrogenase 1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of HSD17B1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr10:88,987,558...88,989,758
Ensembl chr10:88,987,558...88,989,757
|
|
G |
Hsd17b6 |
hydroxysteroid (17-beta) dehydrogenase 6 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of HSD17B6 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 7:2,412,370...2,431,249
Ensembl chr 7:2,412,363...2,431,197 Ensembl chr13:2,412,363...2,431,197
|
|
G |
Hsp90aa1 |
heat shock protein 90 alpha family class A member 1 |
multiple interactions increases expression |
EXP |
tripterine inhibits the reaction [Dextran Sulfate results in increased expression of HSP90AA1 mRNA] |
CTD |
PMID:32470352 |
|
NCBI chr 6:135,107,262...135,112,793
Ensembl chr 6:135,107,271...135,112,775
|
|
G |
Hsp90ab1 |
heat shock protein 90 alpha family class B member 1 |
multiple interactions increases expression |
EXP |
tripterine inhibits the reaction [Dextran Sulfate results in increased expression of HSP90AB1 protein] |
CTD |
PMID:32470352 |
|
NCBI chr 9:17,817,791...17,823,163
Ensembl chr 9:17,817,721...17,823,243
|
|
G |
Hspa1a |
heat shock protein family A (Hsp70) member 1A |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with Dextran Sulfate] results in decreased expression of HSPA1A mRNA |
CTD |
PMID:26271895 |
|
NCBI chr20:4,875,834...4,881,751
Ensembl chr20:4,877,324...4,879,779
|
|
G |
Hspa1b |
heat shock protein family A (Hsp70) member 1B |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with Dextran Sulfate] results in decreased expression of HSPA1B mRNA |
CTD |
PMID:26271895 |
|
NCBI chr20:4,877,638...4,880,112
Ensembl chr20:2,699,712...2,701,815
|
|
G |
Hspg2 |
heparan sulfate proteoglycan 2 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of HSPG2 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 5:155,812,096...155,913,751
|
|
G |
Htr1b |
5-hydroxytryptamine receptor 1B |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of HTR1B mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 8:89,113,984...89,130,830
Ensembl chr 8:89,129,453...89,130,991
|
|